FINAL PROGRAM





WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS A COMPREHENSIVE EDUCATIONAL PROGRAM

2022





PRAGUE / CZECH REPUBLIC

www.iaprd-world-congress.com

Welcome

Acknowledgement	04
	05
Important COVID-related information for IAPRD World Congress 2022	06
Scientific Program	
Floorplan	10
Session Descriptions and Types	11
Sunday, 1 May 2022, Program Overview	12
Sunday, 1 May 2022, Scientific Program	13
Monday, 2 May 2022, Program Overview	18
Monday, 2 May 2022 , Scientific Program	19
Tuesday, 3 May 2022, Program Overview	26
Tuesday, 3 May 2022, Scientific Program	27
Wednesday, 4 May 2022, Program Overview	34
Wednesday, 4 May 2022, Scientific Program	35
Poster Exhibition	36
Information for Abstract Authors	62
Information for Speakers and Chairpersons	63
Travel Grants	64
Index of Authors and Speakers	64
General Congress Information	
Registration	68
CME Accreditation	69
Congress Venue	70
Good to know	72
IAPRD	
About the International Association of Parkinsonism and Related Disorders	76
IAPRD Committees	78
Industry	
Exhibition Floor Plan	82
List of Exhibitors	82
Sponsors and Supporters	83
Corporate Sessions	84
Imprint and Data Protection	86



Welcome to IAPRD 2022 in Prague, Czech Republic

Diagnosing and Treating Movement Disorders in the Era of Personalized Medicine

We are excited to welcome you back in person to the IAPRD congresses! We begin again with Prague, one of Europe's beautiful cities with its hundreds of spires and colorful Baroque buildings set on the Vltava River.

This Congress features a comprehensive educational program in movement disorders led by a global faculty, including classroom seminars, mentorship sessions, discussion of video cases, and enhanced poster interactions. Plenary and parallel sessions are devoted to the latest updates on treatments targeting disease cause, advanced pump and neurosurgical therapies, individualized approaches to patient care, and how genetics and disease subtyping are changing our approach to movement disorders. The final day includes debates on controversial issues in our field.

Prague, our venue for IAPRD 2022, was established more than a thousand years ago and is aptly called "the golden city of a hundred spires." Prague offers glimpses of history at every turn, with its graceful bridges spanning the Vltava River and its colorful Old Town Square with buildings from every era of the city's past. Set in in this enchanting city is the modern Prague Congress Center, designed as an open, friendly, and inspirational location for international meetings such as ours.

This meeting is designed to encourage interactions among colleagues across different countries and career stages and has a personal and collegial feel.



Daniel Truong, MD President, IAPRD



Andreas Puschmann, MD, PhD; Chair, Scientific Program Executive Committee



Joohi Jimenez-Shahed, MD; Co-Chair, Scientific Program Executive Committee



Jan Roth, MD, PhD; Regional Organizing Committee Co-Chair



Irena Rektorová, MD, PhĽ Regional Organizing Committee Co-Chair



Elena Moro, MD, PhD; Regional Organizing Committee Co-Chair



Maja Trošt, MD, PhD; Regional Organizing Committee CO-Chair

IMPORTANT COVID-RELATED INFORMATION ...

A CERTIFICATE PROVIDING EVIDENCE OF FULL VACCINATION AGAINST COVID-19



OR

LABORATORY CONFIRMATION OF HAVING RECOVERED FROM COVID-19 DISEASE IN THE PERIOD NOT LONGER THAN 180 DAYS BEFORE THE DAY OF THE EVENT.



WEAR A RESPIRATORY SYSTEM PROTECTION ARTICLE WITH AT LEAST 94 % FILTERING ABILITY AND WITHOUT EXHALATION VALVE, SUCH AS AN FFP2 CLASS RESPIRATOR (KN95 / N95) OR A NANO FACE MASK.



Important COVID-related information for IAPRD World Congress 2022

Last updated: 01 April 2022

The IAPRD is looking forward to hosting the IAPRD 2022 World Congress as a physical event. The safety of our registrants and conference attendees is of the utmost importance. The COVID-19 policy specified below is based on current pandemic conditions and on the current issued by the Government of the Czech Republic, especially the emergency measure of the Ministry of Health and will be adjusted according to actual conditions at the time of the event.

Please note that travel and on-site conference participation is undertaken at the individual's own risk and responsibility. IAPRD cannot be held financially or legally responsible in cases of infection, time spent in quarantine, or other issues that may arise from COVID-19 or the pandemic. IAPRD is not financially responsible for any COVID-19 testing (PCR, lateral flow tests, etc.) that faculty or on-site participants may be required to undertake.

Before registering, please ensure that you have read this page fully. By registering, you agree to fully comply with all COVID-19 regulations required onsite as defined by the event organiser.

IMPORTANT:

Currently, IAPRD policy requires all registered congress delegates to provide:

A certificate providing evidence of full vaccination against COVID-19 (as defined by the <u>EU Commission</u> at the time of the event).

See the following website for <u>recognition of vaccination certificates from other countries</u>. *OR*

Provide a laboratory confirmation of having recovered from COVID-19 disease in the period not longer than 180 days before the day of the event.

Please note that delegates providing only a valid negative PCR, antigen or antibody test certificate will not be granted access to the congress.

Masks will be mandatory: Delegates will be required to wear a respiratory system protection article with at least 94 % filtering ability and without exhalation valve, such as an FFP2 class respirator (KN95 / N95) or a nano face mask.

It is possible to consume food and drinks in dedicated areas. Please put on a respirator immediately after drinking or eating.

The employees of the Prague Congress Center and local service providers employees and local service providers meet the current regulations set by the Ministry of Health of the Czech Republic. Access to the public areas is permitted only to authorised persons.

The IAPRD is constantly monitoring the COVID-19 status and will follow guidance and advisories from the Ministry of Health in the Czech Republic as well as the standards set forth by the Prague Congress Center.

Please refer to the <u>PCC website</u> or the <u>website created by the Czech government</u> for current measures (congresses fall in the same category as concerts) for updates regarding the IAPRD World Congress 2022 COVID-19 policy.

The current regulations for entry in to the Czech Republic can be viewed here.



SCIENTIFIC PROGRAM

FLOOR PLAN



SESSION DESCRIPTIONS AND TYPES

PLENARY SESSIONS

These sessions will include lectures on phenomenology, and overviews on the pathophysiology, diagnostic and therapeutic approaches to various movement disorders. Each lecture within a plenary theme will be 30 minutes, delivered by world-renowned faculty members.



PARALLEL TRACKS

The sessions within a track are arranged to provide a deep dive into a diagnostic or therapeutic area. Each session will be 30 minutes of interactive lecture (25 minutes of didactic followed by 5 minutes of Q and A).



SEMINARS

In-depth discussions on diagnosis and treatment of selected movement disorders.



GRAND PARADE OF MOVEMENT DISORDERS

An evening video session where both faculty and attendees present pre-selected cases from around the globe to showcase the amazing breadth of movement disorders. This event will be co-hosted by several of our most astute and experienced clinical experts.



SKILLS WORKSHOP

Interactive workshops on practical aspects of therapies for various movement disorders.



COFFEE WITH THE PROFESSOR

Brief mentoring sessions sprinkled throughout the duration of the Congress where young and aspiring clinicians and scientists can engage with a renowned faculty member, in a relaxed setting, over a cup of coffee.



CORPORATE SESSIONS (over Lunch)

These sessions, sponsored by our industry partners, will be held during lunchtime.



ORAL POSTER SESSIONS

Poster authors are expected to present their poster and answer questions by the moderator as well as by the audience of the Oral Poster Session Tour. The author or presenter must be registered for the congress.



RESIDENT AND TRAINEE PROGRAM

Shorter, classroom-style educational sessions.



GET TO KNOW YOUR PEER

This year at IAPRD 2022, we are introducing a new networking opportunity, so you will have the chance to get to know other delegates according to your area of interest. You will receive a sticker indicating your preferred topic(s) in the dedicated Networking Area. The 'Get to Know Your Peers' Area is located on the second floor (please follow the signage). Don't miss out on this opportunity to connect with fellow peers during the coffee break times indicated in the scientific program.

PROGRAM OVERVIEW / SUNDAY, 1 MAY 2022

Room	Plenary Room	South Hall 2A	South Hall 2B	Poster Loft	Exhibition Hall
10:00 - 10:50			Resident and Trainee Presentations		
10:50 - 11:00					
11:00 - 11:50			Resident and Trainee Presentations		
11:50 - 12:00					
12:00 - 12:30			Resident and Trainee Program		
12:30 - 13:00		Lunch	Break		
13:00 - 14:30	Plenary 1: Personalized Medicine in Parkinson Disease				
14:30 - 15:00	Coffee	Break / Get to know yo	ur Peer 📃 / Industry Exl	nibition	
15:00 - 16:30	Plenary Session 2: Future Directions in Diagnostics and Therapy				
16:30 - 17:00	Coffee Break / Get	to know your Peer 📕 /	Industry Exhibition	15.00 10.00	
17:00 - 19:00	Opening Ceremony			Poster Exhibition	



	Resident and Trainee Presentations	South Hall 2B
10:00 – 10:50	Part 1: Parkinson Disease Expert Panel: Hubert Fernandez (Cleveland, United States) Petr Kaňovský (Olomouc, Czech Republic) Irena Rektorová (Brno, Czech Republic) Yaroslau Compta (Barcelona, Spain) (5 minutes oral presentations followed by Q&A)	
RT 1.01	Metabolic changes in dementia with Lewy bodies and Par Speaker: Matej Perovnik (Ljubljana, Slovenia)	kinson's disease
RT 1.02	Correlation of olfactory dysfunction with behavioral symp predominant (TDT) versus akinetic rigid (ART) Parkinson' Speaker: Sahana Panambur (Mysore, India)	toms in tremor s disease
RT 1.03	Comparison of autonomic dysfunction in patients with Paprogressive supranuclear palsy Speaker: Jakub Malkiewicz (Katowice, Poland)	rkinson's disease and
RT 1.04	Placebo-controlled study of neurophysiological paramete patients with Parkinson's disease stage II after a course of magnetic stimulation Speaker: Diamilva Aravitskava (Zaporizhzhva, Ukraine)	rs dynamics in f transcranial
RT 1.05	Neuroprotective effects of estradiol and progesterone in l age groups of naturally menopausal rats: a therapeutic po Parkinson's disease Speaker: Pardeep Kumar (Delhi, India)	brain of different otential drug for
RT 1.06	Levodopa-induced frequency modulation of cortical EEG a mentary motor area of dyskinetic Parkinson's disease pat Speaker: Federica Avantaggiato (Würzburg, Germany)	activity in the supple- ients
RT 1.07	How choroidal thickness is related with Parkinson's disea study	se? A case control
RT 1.08	Correlation of hypothalamic-pituitary adrenal disorders w ment in Parkinson's disease and vascular parkinsonism Speaker: Dilshoda Akramova (Tashkent, Uzbekistan)	ith cognitive impair-
RT 1.09	Sarcopenia in acute ischemic stroke patients and patients disease Speaker: Sonja Mandjikoska (Maribor, Slovenia)	s with Parkinson's
RT 1.10	Probabilistic tractography based structural connectivity of in tremor dominant Parkinson's disease and essential tree Speaker: Shweta Prasad (Bangalore, India)	f the tremor network nor plus syndrome
10:50 - 11:00	Break	

	Resident and Trainee Presentations	South Hall 2B
11:00 – 11:50	Part 2: Other Movement Disorders Expert Panel: Peter Hedera (Nashville, United States) Zvezdan Pirtošek (Ljubljana, Slovenia) Jan Roth (Prague, Czechia) Lorraine V. Kalia (Toronto, Canada)	
RT 2.01	Cross-cultural validation of the Cebuano version of a screening q for Parkinson's disease Speaker: Daryl Dakay (Mandaue City, Philippines)	uestionnaire
RT 2.02	Patients' with Parkinson disease perceptions of palliative care Speaker: Avery Kundrick (Cleveland, United States)	
RT 2.03	Isolated lingual dystonia as a presenting symptom of X-linked dys parkinsonism Speaker: Daryl Dakay (Mandaue City, Philippines)	stonia
RT 2.05	Botulinum toxin type a for blepharospasm Speaker: Alexia Duarte (Curitiba, Brazil)	
RT 2.06	Patient perspective in hereditary ataxia Speaker: Sorina Gorcenco (Lund, Sweden)	
RT 2.07	Non-motor manifestations of myoclonus dystonia on a mixed-eth female with a novel sgce gene nonsense mutation: a case report Speaker: <i>Meliza Angelica De Leon (Metro Manila, Philippines)</i>	nicity Filipino
RT 2.08	Idiopathic NPH patients with worse pre-surgical walk test perform demonstrate the greatest improvement in performance post-VPS Speaker: Avery Kundrick (Cleveland, United States)	nances
RT 2.09	Clinical presentation, comorbidities and treatment of GAD antiboo ed Stiff Person Syndrome Speaker: Giulia Lazzeri (Milan, Italy)	dies associat-
RT 2.10	Aceruloplasminemia – ultra-rare cause of iron accumulation Speaker: Agnieszka Antos (Warsaw, Poland)	
11:50 - 12:00	Break	
	Resident and Trainee Program	South Hall 2B
12:00 - 12:30	Understanding the peer review process: How to get your paper pu Speaker: Hubert Fernandez (Cleveland, United States) Speaker: Huifang Shang (Chengdu, China)	blished
12:30 - 13:00	Lunch Break	
	Plenary Session	Plenary Room
13:00 - 14:30	Plenary Session 1: Personalized Medicine in Parkinson Disease Chair: Andreas Puschmann (Lund, Sweden) Chair: Daniel Truong (Fountain Valley, United States)	

13:00 - 13:30	Plenary Session 1a: Clinical subtyping to individualize patient information and treatment Speaker: Tiago Mestre (Ottawa, Canada)
13:30 - 14:00	Plenary Session 1b: Does Parkinson disease genotype influence treatment decisions? Speaker: Connie Marras (Toronto, Canada)
14:00 - 14:30	Plenary Session 1c: Variations in motor response: Predicting treatment benefit, fluctuations, and dyskinesia Speaker: Roberto Cilia (Milan, Italy)
14:30 - 15:00	Coffee Break / Industry Exhibition
	Get to know your Peer
14:30 – 15:00	Get to know other delegates according to your area of interest. You will receive a sticker indicating your preferred topic(s) in the dedicated Networking Area. The 'Get to Know Your Peers' Area is located on the second floor (please follow the signage).
	Areas of interest: Genetics, Device-aided treatments, Neuroimaging
	Plenary Session Plenary Room
	Plenary Session 2: Future Directions in Diagnostics and Therapy Chair: Joohi Jimenez-Shahed (New York City, United States) Chair: Erik Ch. Wolters (Amsterdam, The Netherlands)
15:00 - 15:30	Plenary Session 2a: Tau and α-synuclein PET: recent developments Speaker: Hitoshi Shimada (Niigata, Japan)
15:30 - 16:00	Plenary Session 2b: The promise of gene therapy for movement disorders Speaker: Roy Alcalay (New York City, United States)
16:00 - 16:30	Plenary Session 2c: Devices, apps and gadgets: how will they change clinical practice? Speaker: Roongroj Bhidayasiri (Bangkok, Thailand)
16:30 - 17:00	Coffee Break / Industry Exhibition
	Get to know your Peer
16:30 – 17:00	Get to know other delegates according to your area of interest. You will receive a sticker indicating your preferred topic(s) in the dedicated Networking Area. The 'Get to Know Your Peers' Area is located on the second floor (please follow the signage). Areas of interest: Pathophysiology, Non-motor symptoms and cognition, Dystonia and hyperkinetic disorders

	Plenary Session	Plenary Room
17:00 - 19:00	Opening Ceremony / IAPRD Lifetime Achievement Award / IAPRD Spotlight on new developments lecture Chair: Andreas Puschmann (Lund, Sweden)	
	Words of Welcome by the IAPRD President Speaker: <i>Daniel Truong (Fountain Valley, United States</i>)	
	Words of Welcome by Regional Organizing Committee Chair Speaker: Irena Rektorová (Brno, Czech Republic)	
	What makes a movement voluntary or involuntary? IAPRD Lifetime Achievement Award Speaker: Mark Hallett (Bethesda, United States)	
	How has genetics changed dystonia? IAPRD Spotlight on new developments lecture Speaker: Michael Zech (Munich, Germany)	
	Words of Welcome by Scientific Program Executive Committee C Speakers: Andreas Puschmann (Lund, Sweden) Joohi Jimenez-Shahed (New York City, United States)	hairs
	At the end of the Opening Ceremony all participants are invited to jo Welcome Reception in the exhibition area.	oin the

SUNDAY, 1 May 2022

PROGRAM OVERVIEW / MONDAY, 2 MAY 2022

Room	Plenary Room	South Hall 2A	South Hall 2B	Poster Loft	Exhibition Hall
08:00 - 09:30	Plenary Session 3: Parkinson Disease Therapeutic Updates: What's New?				
			Resident and Trainee		
09:30 - 10:30	Coffee Break / Po Get to know	oster Exhibition / your Peer <mark></mark>	Classroom I: Understanding Parkinson Disease		Industry Exhibition
10:30 - 12:00	Seminar 1: The Various Forms of Parkinson Disease and Parkinsonism	Parallel Session 2: Myoclonus: Classification and Updates: Consensus Panel Project	Parallel Session 1: Workshop in Atypical Par- kinsonisms and Tremor	09:00 – 17:00 Poster Exhibition	
12:00 - 12:15					
12:15 - 13:45	Lunch Break	Corporate Session II	Corporate Session I		Lunch Break
13:45 - 14:00					
14:00 - 15:30	Plenary Session 4: Update on Disease Modifying Therapies for PD				
15:30 - 16:30	Coffee Break /	Poster Exhibition / Indu	stry Exhibition	Guided Poster Tours I	Coffee with the Professor I
16:30 - 18:00	Seminar 2: Individualized Management of PD Symptoms	Parallel Session 3: Tardive Dyskinesia and Related Syndromes	Skills Workshop 1: Deep Brain Stimu- lation and Pump Treatments		
18:00 - 19:30			IAPRD Annual General Meeting (Business Meeting)		

Seminars Skills Workshop **Corporate Sessions Resident and Trainee Plenary Session** (over Lunch) Program Parallel Track Grand Parade Coffee with Oral Poster Get to know Session the Professor Sessions your Peer

	Plenary Session	Plenary Room
08:00 - 09:30	Plenary Session 3: Parkinson Disease Therapeutic Updates: Wha Chair: Mark Lew (Los Angeles, United States) Chair: Elena Moro (Grenoble, France	t's New?
08:00 - 08:30	Plenary Session 3a: Pharmacological treatment of motor sympto Speaker: Rajesh Pahwa (Kansas City, United States)	ms
08:30 - 09:00	Plenary Session 3b: Medical treatment of nonmotor symptoms Speaker: Ronald Postuma (Montreal, Canada)	
09:00 - 09:30	Plenary Session 3c: Lifestyle and behavioral therapies Speaker: Mark A. Hirsch (Charlotte, United States)	
09:30 - 10:30	Coffee Break / Poster Exhibition / Industry Exhibition	n
	Get to know your Peer	
09:30 - 10:30	Get to know other delegates according to your area of interest. Yo sticker indicating your preferred topic(s) in the dedicated Network 'Get to Know Your Peers' Area is located on the second floor (plea signage). Areas of interest: Genetics, Neuroimaging, Nonmotor symptoms a	u will receive a ing Area. The se follow the and cognition
	Resident and Trainee Program	South Hall 2B
09:35 - 10:20	Resident and Trainee Classroom I: Understanding Parkinson Dise Speaker: Stuart Isaacson (Boca Raton, United States) Speaker: Lorraine V. Kalia (Toronto, Canada)	ease
	Seminar	Plenary Room
10:30 - 12:00	Seminar 1: The Various Forms of Parkinson Disease and Parkinson Chair: Connie Marras (Toronto, Canada) Chair: Mark Lew (Los Angeles, United States)	onism
10:30 - 11:00	Seminar 1a: Does the PD clinical subtype or biomarker profile inf ment decisions? Speaker: Mark Lew (Los Angeles, United States)	luence treat-
11:00 - 11:30	Seminar 1b: Recent developments in genetics of parkinsonisms Speaker: Vincenzo Bonifati (Rotterdam, The Netherlands)	
11:30 - 12:00	Seminar 1c: Differential diagnosis of parkinsonisms – new aspec Speaker: Heinz Reichmann (Dresden, Germany)	ts

	Parallel Sessions	South Hall 2B
10:30 - 12:00	Parallel Session 1: Workshop in Atypical Parkinsoni Chair: Paola Sandroni (Rochester, United States) Chair: Ruth Walker (New York City, United States)	sms and Tremor
10:30 - 11:00	Parallel 1a: Workshop on PSP and CBD Speaker: Adam Boxer (San Francisco, United States)	
11:00 - 11:30	Parallel 1b: Workshop on MSA and other atypical pa Speaker: Wassilios Meissner (Bordeaux, France)	rkinsonisms
11:30 - 12:00	Parallel 1c: Workshop on tremors Speaker: <i>Elan Louis (Dallas, United States)</i>	
	Parallel Sessions	South Hall 2B
10:30 - 12:00	Parallel Session 2: Myoclonus: Classification and U Consensus Panel Project – Tribute to Mr. Norman Seiden – Chair: John Caviness (Phoenix, United States) Chair: Marina de Koning-Tijssen (Groningen, The Neth	pdates: nerlands)
10:30 - 11:00	Parallel 2a: Classification of Myoclonus Speaker: John Caviness (Phoenix, United States) Speaker: Marina de Koning-Tijssen (Groningen, The N	letherlands)
11:00 - 11:30	Parallel 2b: Genetic evaluation and etiologies/syndr Speaker: Sterre van der Veen (Groningen, The Netherl	omes of myoclonus lands)
11:30 - 12:00	Parallel 2c: Electrophysiological tools to decipher je Speaker: Anna Latorre (London, United Kingdom)	erky movements
12:00 - 14:00	Lunch Break / Poster Exhibition / Indu	stry Exhibition
	Corporate Session S	South Hall 2A / South Hall 2B
12:15 - 13:45	Corporate Sessions See page 84	
	Plenary Session	Plenary Room
14:00 - 15:30	Plenary 4: Update on Disease Modifying Therapies Chair: Etienne Hirsch (Paris, France) Chair: Tanya Simuni (Chicago, United States)	for Parkinson Disease
14:00 - 14:30	Plenary Session 4a: Synuclein targeted therapeutic Speaker: Jeffrey Kordower (Tempe, United States)	s: rationale and trial update
14:30 - 15:00	Plenary Session 4b: GBA and LRRK2 targeting thera update Speaker: <i>Tanya Simuni (Chicago, United States)</i>	pies: rationale and trial

15:00 – 15:30	Plenary Session 4c: Implanted gene and cell therapies for PD: rationale and trial update Speaker: Håkan Widner (Lund, Sweden)
15:30 - 16:30	Coffee Break / Poster Exhibition / Industry Exhibition
	Oral Poster Sessions Poster Loft
15:30 - 16:30	Guided Poster Tours I (2 minute oral presentations followed by Q&A)
	Guided Poster Tour: Basic Neuroscience, Imaging, and Biomarkers Moderator: Etienne Hirsch (Paris, France) Moderator: Jon Stoessl (Vancouver, Canada)
P 001 (GPT)	In silico study of Orexin on subthalamic nucleus neuron electrophysiology towards Parkinson's disease Speaker: Chitaranjan Mahapatra (Mumbai, India)
P 006 (GPT)	Preclinical diagnosis of Parkinson's disease: upgraded and new approaches Speaker: <i>Michael Ugrumov (Moscow, Russian Federation)</i>
P 007 (GPT)	Head-to-head comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome Speaker: Elon Wallert (Amsterdam, Netherlands)
P 012 (GPT)	Understanding correlation between diffusion MRI-derived white-matter organi- zation and clinical measures in Parkinson's disease patients with freezing of gait Speaker: Virendra Mishra (Las Vegas, United States)
P 014 (GPT)	Effects of levodopa on functional connectivity in Parkinson's disease patients with Mild Cognitive Impairment Speaker: Karthik Sreenivasan (Las Vegas, United States)
P 016 (GPT)	Gray matter abnormalities in myotonic dystrophy type 1: a voxel-wise meta- analysis Speaker: Qirui Jiang (Chengdu, China)
	Guided Poster Tour: Choreas, Ataxias, Tremor Moderator: Pramod Pal (Bengaluru/Karnataka, India)
P 189 (GPT)	Functional chorea diagnosed in a patient with schizophrenia treated with paliperidone: extrapyramidal side effect or functional? Speaker: Tuğçe Saltoğlu (Ankara, Turkey)
P 191 (GPT)	Fingolimod-responsive complex hyperkinetic movement disorder in neuro- myelitis optica spectrum disorder Speaker: <i>Ross Elizabeth Cortes (Cebu City, Philippines)</i>
P 192 (GPT)	Characteristics of tics in follow-up study of community-based high risk cohort of 2511 children Speaker: Natalia Szejko (Warsaw, Poland)

P 195 (GPT)	Moving toes in 28-year-old woman: a video case report Speaker: Cecylia Rajczewska-Oleszkiewicz (Warszawa, Poland)
P 197 (GPT)	Common pitfalls in recognition of an age old malady: edentulous stereotypy Speaker: Soaham Desai (Anand, India)
P 206 (GPT)	A comprehensive study of the association between autonomic and clinical severity in spinocerebellar ataxia type 3 patients Speaker: Dibashree Tamuli (New Delhi, India)
P 208 (GPT)	Prevalence of essential tremor in rural Gujarat, India Speaker: <i>Soaham Desai (Anand, India)</i>
	<mark>Guided Poster Tour: Dystonia</mark> Moderator: Alberto Albanese (Milan, Italy) Moderator: Michael Zech (Munich, Germany)
P 171 (GPT)	Effects of botulinum toxin type A in Meige's syndrome Speaker: <i>Alexia Duarte (Curitiba, Brazil)</i>
P 175 (GPT)	Biopsychosocial aspect of patients with X-Linked Dystonia-Parkinsonism: Its implications on quality of life Speaker: Aljeirou Alcachupas (Iloilo City, Philippines)
P 176 (GPT)	Depression impact on subjective and objective severity of cervical and seg- mental dystonia Speaker: Vlada Meļņikova (Rīga, Latvia)
P 177 (GPT)	Clinical aspects of patients with blepharospasm in Latvia: one center study Speaker: <i>Madara Kalniņa (Riga, Latvia)</i>
P 178 (GPT)	Data of P. Stradins Clinical University Hospital Dystonia Register: time from symptoms to diagnosis and treatment of blepharospasm Speaker: Madara Kalniņa (Riga, Latvia)
P 179 (GPT)	Comparing the features of cervical dystonia subtypes: a retrospective study in Pakistan
P 185 (GPT)	Speaker: Arooj Fatima (Lanore, Pakistan) Mutation screening and burden analysis of IMPDH2 in dystonia in a Chinese population Speaker: Junyu Lin (Chengdu, China)
P 187 (GPT)	Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia Speaker: Jarosław Sławek (Gdansk, Poland)
	Guided Poster Tour: PD clinical assessment Moderator: Jan Roth (Prague, Czech Republic) Moderator: Connie Marras (Toronto, Canada)
P 068 (GPT)	Amantadine treatment in Parkinson's disease patients as a modulatory factor of SARS-Cov-2 infection Speaker: Stanislaw Szlufik (Warsaw, Poland)

P 079 (GPT)	Comparison of autonomic dysfunction in essential tremor and Parkinson's dis- ease: a pilot study Speaker: Jakub Malkiewicz (Katowice, Poland)
P 089 (GPT)	Correlation between age and positive and negative affect in Parkinson's disease Speaker: <i>Elly Robles (Monterrey, Mexico)</i>
P 130 (GPT)	If not insulin resistance so what? Comparison fasting glycaemia in idiopathic Parkinson's disease and atypical parkinsonism Speaker: Tomasz Chmiela (Katowice, Poland)
P 131 (GPT)	Burning mouth syndrome to oral cenesthopathy: a spectrum of neuropsychiatric and sensory complications in neurodegenerative parkinsonism Speaker: Jeryl Ritzi Tan Yu (Cleveland, United States)
P 137 (GPT)	Model of virtual communication of the Reference center for invasive methods of treatment of Parkinson's disease during the COVID-19 pandemic Speaker: Vita Komen (Rijeka, Croatia)
P 141 (GPT)	A Croatian tertiary center experience on the impact of the COVID-19 pandemic on Parkinson's disease: a cross-sectional telephone study Speaker: Mario Hero (Rijeka, Croatia)
P 143 (GPT)	Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine Speaker: Jarosław Sławek (Gdańsk, Poland)
P 147 (GPT)	Violation of motor and non-motor functions in patients with COVID-19 with oral pathology Speaker: Malika Giyazova (Bukhara, Uzbekistan)
	<mark>Guided Poster Tour: PD Genetics</mark> Moderator: Vincenzo Bonifati (Rotterdam, The Netherlands) Moderator: Gençer Genç (Istanbul, Turkey)
P 051 (GPT)	Polygenic resilience inheritance modulates the penetrance of Parkinson's disease genetic risk factors Speaker: <i>Hui Liu (Tuebingen, Germany)</i>
P 053 (GPT)	Diagnostic utility of whole-exome sequencing in early onset and familial Parkinson's disease: Preliminary findings in a regional centre study Speaker: Valentino Rački (Rijeka, Croatia)
P 055 (GPT)	PLA2G6-associated neurodegeneration in three different populations-case series Speaker: Lukasz Milanowski (Jacksonville, United States)
P 056 (GPT)	Plasma miR-153 and miR-223 levels as potential biomarkers in Parkinson's disease
P 060 (GPT)	Heads – It's Parkinson's; tails – it's cancer, a kindred of Parkinsonism and Malignancies Speaker: Meera Matta (Chandigarh, India)

P 061 (GPT)	Green tea intake and Parkinson's disease progression: a Mendeli zation study Speaker: Chunvu Li (Chenadu, China)	an randomi-
P 062 (GPT)	Genomic analyses of a large Swedish multi-incident kindred with dominant Parkinson's disease with dementia Speaker: Emil Ygland Rödström (Lund, Sweden)	autosomal
P 066 (GPT)	Charcot-Marie-Tooth Disease associated with Parkinson Disease Speaker: Hector Pacheco Mendoza (Mexico City, Mexico)	, about a case
	Coffee with the Professor	Exhibition Hall
15:30 - 16:30	Coffee with the Professor I Chair: Christine Klein (Lübeck, Germany)	
	Seminar	Plenary Room
16:30 - 18:00	Seminar 2: Individualized Management of PD Symptoms Chair: Petr Kaňovský (Olomouc, Czech Republic) Chair: Roberto Cilia (Milan, Italy)	
16:30 - 17:00	Seminar 2a: Freezing of gait – is there anything that really helps? Speaker: Simon Lewis (Sydney, Australia)	?
17:00 - 17:30	Seminar 2b: Cognition and psychiatric functions Speaker: Irena Rektorová (Brno, Czech Republic)	
17:30 – 18:00	Seminar 2c: Individualized care for patients with advanced or terr and related disorders Speaker: Stefan Lorenzl (Salzburg, Austria)	minal stage PD
	Skills Workshops	South Hall 2B
16:30 - 18:00	Skills Workshop 1: Deep Brain Stimulation and Pump Treatments Chair: Bettina Debû (Grenoble, France) Chair: Zvezdan Pirtošek (Ljubljana, Slovenia)	
16:30 - 17:00	Skills Workshop 1a: DBS programming technologies and strategies Speaker: Joohi Jimenez-Shahed (Houston, United States)	es
17:00 - 17:30	Skills Workshop 1b: Pump therapies for Parkinson disease Speaker: Per Odin (Lund, Sweden)	
17:30 - 18:00	Skills Workshop 1c: Cases / examples Speaker: <i>Per Odin (Lund, Sweden)</i> Speaker: Jinyoung Youn (Seoul, South Korea)	

	Parallel Sessions	South Hall 2A
16:30 - 18:00	Parallel Session 3: Tardive Dyskinesia and Related Syndromes Chair: William Ondo (Houston, United States) Chair: Peter van Harten (Maastricht, The Netherlands)	
16:30 - 17:00	Parallel 3a: A review of purported pathophysiological explanation syndromes Speaker: Pavel Mohr (Prague, Czech Republic)	s for tardive
17:00 - 17:30	Parallel 3b: Controversies in tardive disorders: Implications for tr decisions Speaker: Peter van Harten (Maastricht, The Netherlands)	eatment
17:30 - 18:00	Parallel 3c: Controversy in tardive disorders: Are VMAT2 inhibitor masking with neuroleptics for treating tardive syndromes? Speaker: William Ondo (Houston, United States)	rs better than
	Internal Sessions	South Hall 2B
18:00 - 19:30	IAPRD Annual General Meeting (Business Meeting, Full IAPRD M	embers only)

PROGRAM OVERVIEW / TUESDAY, 3 MAY 2022

Room	Plenary Room	South Hall 2A	South Hall 2B	Poster Loft	Exhibition Hall
08:00 - 09:30	Plenary Session 5: How Genetics Have Changed Hyper- kinetic Syndromes				
09:30 - 10:30	Coffee Break / P Get to know	oster Exhibition / your Peer 🔜	Resident and Trair Classroom 2: Phenomenology Rarer Movemen Disorders, Under standing Clinica Genetics	nee of t I	Industry Exhibition
10:30 - 12:00	Seminar 3: Personalized Approach to Patients with Complex Move- ment Disorders		Parallel Session Clinical Worksho with Videos: Diagnostic Approa to Patients with Hyp kinetic Syndrome	4: p ach per- 9:00 – 17:00 Poster Exhibition	
12:00 - 12:15	Lunch Brook / Postor				Lunch Brook / Postor
12:15 - 13:45	Exhibition /	Corporate Session III	Corporate Session	1 IV	Exhibition /
13:45 - 14:00					
14:00 - 15:30	Plenary 6: Update on Therapies for Hyperkinetic Syndromes				
15:30 - 16:30	Coffee Break /	Poster Exhibition / Ind	ustry Exhibition	Guided Poster	Coffee with the
16:30 - 18:00	Seminar 4: Rare Treatable Movement Disorders		Skills Workshop Botulinum Toxir Injections for Cervical Dystoni	Poster Exhibition	11012330111
18:00		W	ine and Cheese Rec	eption	
18:00 – 20:00	Grand Parade of Movement Disorders Video Session				
Plenary S	Session Semin	ars Skills Parade Coffe	Workshop	Corporate Sessions (over Lunch) Oral Poster	Resident and Trainee Program Get to know

the Professor

Sessions

your Peers

Session

SCIENTIFIC PROGRAM / TUESDAY, 3 MAY 2022

	Plenary Session	Plenary Room	
08:00 - 09:30	Plenary Session 5: How Has Genetics Changed Movement Disord Melvin Yahr Lecture Chair: Alberto Albanese (Milan, Italy) Chair: Michael Zech (Munich, Germany)	lers /	
08:00 - 08:30	Plenary Session 5a: Ataxia and hereditary spastic paraplegia Speaker: Martin Paucar Arce (Stockholm, Sweden)		
08:30 - 09:00	Plenary Session 5b: Chorea Speaker: Ruth Walker (New York City, United States)		
09:00 - 09:30	Plenary Session 5c: Melvin Yahr Lecture 2022: How has genetics reshaped the field of movement disorders? Speaker: Christine Klein (Lübeck, Germany)		
09:30 - 10:30	Coffee Break / Poster Exhibition / Industry Exhibitio	n	
	Get to know your Peer		
09:30 - 10:30	Get to know other delegates according to your area of interest. You will receive a sticker indicating your preferred topic(s) in the dedicated Networking Area. The 'Get to Know Your Peers' Area is located on the second floor (please follow the signage). Areas of interest: Pathophysiology, Device-aided treatments, Dystonia and hyper-kinetic disorders		
	Resident and Trainee Program	South Hall 2B	
09:35 – 10:20	Resident and Trainee Classroom 2: Phenomenology of Rarer Mov ders, Understanding Clinical Genetics Speaker: Jinyoung Youn (Seoul, Korea) Speaker: Petr Dušek (Prague, Czech Republic)	vement Disor-	
	Seminar	Plenary Room	
10:30 – 12:00	Seminar 3: Personalized Approach to Patients with Complex Mov Disorders Chair: Aida Kondybayeva (Almaty, Kazakhstan) Chair: Zoltan Mari (Las Vegas, United States)	vement	
10:30 - 11:00	Seminar 3a: Deep phenotyping in the adult movement disorders of Speaker: Kailash Bhatia (London, United Kingdom)	clinic	
11:00 - 11:30	Seminar 3b: Diagnostic yield and interpretation of NGS tests Speaker: Andreas Puschmann (Lund, Sweden)		
11:30 - 12:00	Seminar 3c: Childhood-onset complex movement disorders: Phe genotype Speaker: <i>Riadh Gouider (Tunis, Tunisia)</i>	notype and	

SCIENTIFIC PROGRAM / TUESDAY, 3 MAY 2022

	Parallel Sessions	South Hall 2B
10:30 - 12:00	Parallel Session 4: Clinical Workshop with Videos: Patients with Hyperkinetic Syndromes Chair: Pramod Pal (Bengaluru, Karnataka, India) Chair: Raja Mehanna (Houston, United States)	Diagnostic Approach to
10:30 - 11:00	Parallel 4a: Dystonias Speaker: Alberto Albanese (Milan, Italy)	
11:00 – 11:30	Parallel 4b: Ataxias Speaker: Shinsuke Fujioka (Fukuoka, Japan)	
11:30 - 12:00	Parallel 4c: Episodic and other rare movement disc Speaker: Anhar Hassan (Rochester, United States)	orders
12:00 - 14:00	Lunch Break / Poster Exhibition / Ind	ustry Exhibition
	Corporate Session	South Hall 2A / South Hall 2B
12:15 – 13:45	Corporate Sessions See page 84 & 85	
	Plenary Session	Plenary Room
14:00 - 15:30	Plenary 6: Update on Therapies for Hyperkinetic S Chair: <i>Heinz Reichmann (Dresden, Germany)</i> Chair: <i>Evžen Růžička (Prague, Czech Republic)</i>	yndromes
14:00 - 14:30	Plenary Session 6a: Treatment of hyperkinetic dise Speaker: Dirk Dressler (Hannover, Germany)	orders: from common to rare
14:30 - 15:00	Plenary Session 6b: Surgical treatments for tremo Speaker: Andres Lozano (Toronto, Canada)	rs, tics, choreas, myoclonus
15:00 - 15:30	Plenary Session 6c: Huntington disease: update or Speaker: <i>Anna Rita Bentivoglio (Rome, Italy)</i>	n clinical trials
15:30 - 16:30	Coffee Break / Poster Exhibition / Ind	lustry Exhibition
	Oral Poster Sessions	Poster Loft
15:30 – 16:30	Guided Poster Tours II (2 minute oral presentations followed by Q&A) Guided Poster Tour: Neurosurgery and Deep Brain Moderator: <i>Vladimira Vuletić (Rijeka, Croatia)</i> Moderator: <i>Raja Mehanna (Houston, United States)</i>	Stimulation
P 024 (GPT)	Reprogramming frequency in clinical practice: 6-m DBS for Parkinson's disease subjects in ADROIT Speaker: Sergiu Groppa (Mainz, Germany)	nonths post-implantation of
P 026 (GPT)	Identification of suboptimal response to STN-DBS Speaker: <i>Ivan Rektor (Brno, Czech Republic)</i>	in Parkinson's disease

Eleven-year outcomes from the deep brain stimulation in early-stage Parkinson's disease pilot clinical trial Speaker: <i>Mallory Hacker (Nashville, United States)</i>
Improving the accuracy of DBS and other stereotactic neurosurgeries using a 3D-printed skull for preoperative target practice Speaker: Hargunbir Singh (Chandigarh, India)
Clinical milestones demonstrate compression of morbidity in patients with Parkinson`s disease treated by deep brain stimulation of the subthalamic nucleus
Speaker: Nils Schnalke (Dresden, Germany)
Compared effects of magnetic-resonance guided ultrasound (MRgFUS) and deep brain stimulation (DBS) in a 58 year old Parkinson's disease patient Speaker: <i>Eliša Papić (Rijeka, Croatia)</i>
Subthalamic recordings in chronically implanted parkinsonian patients Speaker: Chiara Palmisano (Würzburg, Germany)
STN DBS improves balance disorders in Parkinson's disease patients and im- pacts the disease progression Speaker: Stanislaw Szlufik (Warsaw, Poland)
Guided Poster Tour: PD cognition, Other Parkinsonian Disorders Moderator: Irena Rektorová (Brno, Czech Republic) Moderator: Paola Sandroni (New York City, United States)
Clinical evaluation of neuropsychiatric symptoms in patients with Parkinson's disease during COVID-19 pandemic: risk factors Speakers: <i>Marufjon Salokhiddinov (Aberdeen, United Kingdom)</i>
The role of dopaminergic therapy on cognition in Parkinson's disease Speaker: Leila Montaser Kouhsari (Palo Alto, United States)
A novel C19ORF12 mutation in a MPAN family with the treatment of deferiprone Speaker: Sihui Chen (Chengdu, China)
Lipid profile as a differentiating factor in PSP-Richardson-Steele syndrome and Corticobasal syndrome Speaker: Natalia Madetko (Warsaw, Poland)
Prediction of disability in multiple system atrophy based on machine learning algorithm Speaker: <i>Lingyu Zhang (Chengdu, China</i>)
Can restless legs syndrome be a predictor of parkinsonism in patients with migraine comorbid with hypertension? Speaker: <i>Munisakhon Gulova (Bukhara, Uzbekistan)</i>

	Guided Poster Tour: PD Rehabilitation and Gait Moderator: <i>Mark Hallett (Bethesda, United States)</i> Moderator: <i>Mark A. Hirsch (Charlotte, United States)</i>
P 071 (GPT)	Prevalence and associated factors of malnutrition in patients with Parkinson's disease using CONUT and GNRI Speaker: Zheng Jiang (Chengdu, China)
P 074 (GPT)	Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems Speaker: <i>Merve Sapmaz Atalar (İstanbul, Turkey)</i>
P 216 (GPT)	Detection of Parkinson's disease using a deep neural network based on gait analysis Speaker: Abhishek Baipai (Barabanki, India)
P 219 (GPT)	Physical interventions for people with Parkinson's disease: results from a Cochrane systematic review and network meta-analysis Speaker: Moritz Ernst (Cologne, Germany)
P 223 (GPT)	Impact of COVID-19 pandemic on eating behavior and body mass index in patients with Parkinson's disease of Northeastern México Speaker: Cynthia Karyna Lopez-Botello (Monterrey, Mexico)
P 225 (GPT)	Addressing fear of falling avoidance behavior in Parkinson's disease: a theoretical framework to inform clinical practice Speaker: Merrill R. Landers (Las Vegas, United States)
	Guided Poster Tour: Parkinson disease Therapy Moderator: Hubert Fernandez (Cleveland, United States) Moderator: Maria Fiorella Contarino (Leiden, The Netherlands)
P 094 (GPT)	Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for treatment of Parkinson disease Speaker: <i>Ryan R. Walsh (Princeton, United States)</i>
P 097 (GPT)	Real-world effect of age on long-term effectiveness and safety of levodopa- carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study Speaker: Mihaela Simu (Timisoara, Romania)
P 102 (GPT)	Levodopa-Carbidopa intestinal gel may improve treatment-resistant freezing of gait Speaker: Melanie Shackleford (Las Vegas, United States)
P 112 (GPT)	Effect of istradefylline dosage on unified Parkisons' disease rating scale (UPDRS) III-ON scores: results from four randomized clinical trials Speaker: Jaime Kulisevsky (Barcelona, Spain)
P 113 (GPT)	SAGE-718 in Parkinson's disease mild cognitive impairment: results from the Phase 2 PARADIGM Study Speaker: Katrina Paumier (Cambridge, United States)
P 116 (GPT)	A novel treatment for Apraxia of Eyelid Opening using a pulsating headband: a single-centre pilot study Speaker: Shivani Arjun (Chandigarh, India)

P 117 (GPT)	Bezoar and catheter knotting as rare complications of levodopa carbidopa intestinal gel therapy Speaker: Tužeo Saltožiu (Ankara, Turkov)
P 124 (GPT)	Adverse effects of levodopa/carbidopa intrajejunal gel treatment: a single center long-term prospective study Speaker: Sandro Ibrulj (Ljubljana, Slovenia)
P 127 (GPT)	Setting the TEMPO: A phase 3 program to investigate tavapadon, a selective D1/D5 partial agonist, for Parkinson's disease Speaker: Hubert Fernandez (Cleveland, United States)
P 128 (GPT)	Advanced therapies for Parkinson's disease (PD) in the age of telehealth Speaker: Zoltan Mari (Las Vegas, United States)
	Guided Poster Tour: Resident and Trainee Poster Presentations I Moderator: Daniel Truong (Fountain Valley, United States) Moderator: Joohi Jimenez-Shahed (New York City, United States)
RT 1.01	Metabolic changes in dementia with Lewy bodies and Parkinson's disease Speaker: <i>Matej Perovnik (Ljubljana, Slovenia</i>)
RT 1.02	Correlation of olfactory dysfunction with behavioral symptoms in tremor pre- dominant (TDT) versus akinetic rigid (ART) Parkinson's disease Speaker: Sahana Panambur (Mysore, India)
RT 1.03	Comparison of autonomic dysfucntion in patients with Parkinson's disease and progressive supranuclear palsy Speaker: Jakub Malkiewicz (Katowice, Poland)
RT 1.04	Placebo-controlled study of neurophysiological parameters dynamics in patients with Parkinson's disease stage II after a course of transcranial magnetic stimulation Speaker: Diamilya Aravitskaya (Zaporizhzhya, Ukraine)
RT 1.05	Neuroprotective effects of estradiol and progesterone in brain of different age groups of naturally menopausal rats.: a therapeutic potential drug for Parkin- son's disease Speaker: Pardeen Kumar (Delbi, India)
RT 1.06	Levodopa-induced frequency modulation of cortical EEG activity in the supple- mentary motor area of dyskinetic Parkinson's disease patients Speaker: Federica Avantaggiato (Würzburg, Germany)
RT 1.07	How choroidal thickness is related with Parkinson's disease? A case control study Speaker: Arooj Fatima (Lahore, Pakistan)
RT 1.08	Correlation of hypothalamic-pituitary adrenal disorders with cognitive impairment in Parkinsons disease and vascular parkinsonism Speaker: Dilshoda Akramova (Tashkent, Uzbekistan)
RT 1.09	Sarcopenia in acute ischemic stroke patients and patients with Parkinson's disease Speaker: Sonja Mandjikoska (Maribor, Slovenia)

SCIENTIFIC PROGRAM / TUESDAY, 3 MAY 2022

RT 1.10	Probabilistic tractography based structural connectivity of the tr in tremor dominant Parkinson's disease and essential tremor plu Speaker: Shweta Prasad (Bangalore, India)	remor network Is syndrome
	Guided Poster Tour: Resident and Trainee Poster Presentations Moderator: Ivan Rektor (Brno, Czech Republic)	II
RT 2.01	Cross-cultural validation of the Cebuano version of a screening of for Parkinson's disease Speaker: Daryl Dakay (Mandaue City, Philippines)	questionnaire
RT 2.02	Patients' with Parkinson disease perceptions of palliative care Speaker: Avery Kundrick (Cleveland, United States)	
RT 2.03	Isolated lingual dystonia as a presenting symptom of X-linked dy parkinsonism Speaker: Daryl Dakay (Mandaue City, Philippines)	vstonia
RT 2.04	Structural and functional brain abnormalities in idiopathic cervic a multimodal meta-analysis Speaker: Xiang Huang (Chengdu, China)	al dystonia:
RT 2.05	Botulinum toxin type a for blepharospasm Speaker: <i>Alexia Duarte (Curitiba, Brazil)</i>	
RT 2.06	Patient perspective in hereditary ataxia Speaker: Sorina Gorcenco (Lund, Sweden)	
RT 2.07	Non-motor manifestations of myoclonus dystonia on a mixed-et female with a novel sgce gene nonsense mutation: a case report Speaker: Meliza Angelica De Leon (Metro Manila, Philippines)	hnicity Filipino
RT 2.08	Idiopathic NPH patients with worse pre-surgical walk test perfor demonstrate the greatest improvement in performance post-VPS Speaker: Avery Kundrick (Cleveland, United States)	mances S
RT 2.09	Clinical presentation, comorbidities and treatment of GAD antibo associated Stiff Person Syndrome Speaker: Giulia Lazzeri (Milan, Italy)	odies
RT 2.10	Aceruloplasminemia – ultra-rare cause of iron accumulation Speaker: Agnieszka Antos (Warsaw, Poland)	
	Coffee with the Professor	Exhibition Hall
15:30 - 16:30	Coffee with the Professor II Elena Moro (Grenoble, France) Kailash Bhatia (London, United Kingdom)	
	Seminar	Plenary Room
16:30 - 18:00	Seminar 4: Rare Treatable Movement Disorders Chair: Marina de Koning-Tijssen (The Netherlands) Chair: Petr Dušek (Prague, Czech Republic)	

16:30 - 17:00	Seminar 4a: When to suspect and how to diagnose rare treatable genetic move- ment disorders Speaker: Katja Lohmann (Lübeck, Germany)		
17:00 - 17:30	Seminar 4b: Treatment strategies for Wilson disease— choice, effic evidence Speaker: Peter Hedera (Nashville, USA)	cacy and	
17:30 - 18:00	Seminar 4c: Other rare movement disorders with treatments target cause Speaker: Hyder Jinnah (Atlanta, United States)	ting disease	
	Skills Workshops	South Hall 2B	
16:30 - 18:00	Skills Workshop 2: Botulinum Toxin Injections for Cervical Dystonia Chair: Jarosław Sławek (Gdańsk, Poland) Chair: Jörg Wissel (Berlin, Germany)	a	
16:30 - 17:00	Skills Workshop 2a: Recognizing cervical dystonia patterns Speaker: Jarosław Sławek (Gdańsk, Poland)		
17:00 - 17:30	Skills Workshop 2b: Practical issues in muscle selection and ultras guidance Speaker: Anna Castagna (Milan, Italy)	sound	
17:30 - 18:00	Skills Workshop 2c: Muscle identification and injection Speaker: Stefan Meng (Vienna, Austria)		
	Grand Parade of Movement Disorders	Plenary Room	
18:00 – 20:00	Grand Parade of Movement Disorders Video Session Chair: Kailash Bhatia (London, United Kingdom) Chair: Raymond Rosales (Quezon City, Philippines) Chair: Ruth Walker (New York City, United States) Chair: Bettina Balint (Zurich, Switzerland) Video presenters: Kadriye Irem Carus (Istanbul, Turkey) Tiziana De Santis (Milan, Italy) Anhar Hassan (Rochester, United States) Justyna Kaczyńska (Warsaw, Poland) Jonáš Kunst (Brno, Czech Republic) Zoltan Mari (Las Vegas, United States) Tuğçe Saltoğlu (Ankara, Turkey)		

Time for Questions and Answers will follow presentation of each video case.

PROGRAM OVERVIEW / WEDNESDAY, 4 MAY 20222

Room	Plenary Room	Soth Hall 2A	South Hall 2B	Poster Loft	Exhibition Hall
08:00 - 09:30	Plenary Session 7: Selecting Patients for Neurosurgery and Neuromodulation				
09:30 - 10:00	Coffee Break				
10:00 - 11:00	Plenary Session 8: Controversy: MRI and PET Imaging Can Determine Disease Subtype, Monitor Disease Progression, and Individualize Treatment in PD				
11:00 - 12:10	Best Papers in Parkinsonism and Related Disorders and Clinical Parkinsonism and Related Disorders				
12:10 - 12:50	IAPRD 2022 Congress Awards and Closing Ceremony				



34

	Plenary Session	Plenary Room
08:00 - 09:30	Plenary Session 7: Selecting Patients for Neurosurgery and Neur Chair: Joohi Jimenez-Shahed (New York City, United States) Chair: Joachim Krauss (Hannover, Germany)	romodulation
08:00 - 08:30	Plenary Session 7a: DBS Surgery in PD: earlier or later? Speaker: Elena Moro (Grenoble, France)	
08:30 - 09:00	Plenary Session 7b: DBS surgery in dystonia: clinical and genetic ations Speaker: Ioannis Isaias (Würzburg, Germany)	consider-
09:00 - 09:30	Plenary Session 7c: Noninvasive cortical stimulation: who, where how? Speaker: Hartwig Siebner (Copenhagen, Denmark)	e, when, and
09:30 - 10:00	Coffee Break	
	Plenary Session	Plenary Room
10:00 – 11:00	Plenary Session 8: Controversy: MRI and PET Imaging Can Deter Subtype, Monitor Disease Progression, and Individualize Treatme Chair: Elena Moro (Grenoble, France) Chair: Hartwig Siebner (Copenhagen, Denmark)	mine Disease ent in PD
10:00 - 10:30	Plenary Session 8a: Yes Speaker: Per Borghammer (Aarhus, Denmark)	
10:30 - 11:00	Plenary Session 8b: No Speaker: Jon Stoessl (Vancouver, Canada)	
	Plenary Session	Plenary Room
11:00 – 12:10	Best Papers in Parkinsonism and Related Disorders and Clinical and Related Disorders Chair: Vincenzo Bonifati (Rotterdam, The Netherlands) Chair: Hubert Fernandez (Cleveland, United States) Chair: Huifang Shang (Chengdu, China)	Parkinsonism
11:00 - 11:35	PRD journal Speaker: Zoltan Mari (Las Vegas, United States)	
11:35 – 12:10	CPRD journal Speaker: <i>Marie-Hélène Saint-Hilaire (Boston, United States)</i>	
	Plenary Session	Plenary Room
	IAPRD 2022 Congress Awards and Closing Ceremony	

We kindly ask all poster authors to be available at their poster in order to enable visits and talks of participants during the following times:

• Even poster numbers: Monday, 2 May, 2022 from 12:15 – 13:15 (during lunch break)

• Uneven (odd) poster numbers: Tuesday, 3 May, 2022 from 12.15 – 13:15 (during lunch break)

Topic: Basic Neuroscience (excluding Genetics)			
P 001 (GPT)	In silico study of Orexin on subthalamic nucleus neuron electrophysiology towards Parkinson's disease <u>C. Mahapatra</u> ¹ , R. Manchanda ¹ ¹ Indian Institute of Technology Bombay, Bio Sciences & Bio Engineering, Mumbai, India		
P 002	Orthostatic hypotension: a mini-review <u>A. Ovchynnykova</u> ¹ , Y. Trufanov ¹ , N. Svyrydova ¹ ¹ Shupyk National Healthcare University of Ukraine, Neurology, Kyiv, Ukraine		
Topic: Imaging and Biomarkers			
P 006 (GPT)	Preclinical diagnosis of Parkinson's disease: upgraded and new approaches <u>M. Ugrumov</u> ¹ ¹ Institute of Developmental Biology, Russian Academy of Sciences, Laboratory of Neural and Neuroendo- crine Regulations, Moscow, Russian Federation		
P 007 (GPT)	Head-to-head comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome <u>E. Wallert</u> ¹ , E. Letort ² , F. van der Zant ³ , A. Winogrodzka ⁴ , H. Berendse ⁵ , M. Beudel ⁶ , R. de Bie ⁶ , J. Booij ¹ , P. Raijmakers ⁷ , E. van de Giessen ⁸ ¹ Amsterdam UMC, Location AMC, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands, ² Northwest Clinics, Location Alkmaar / Spaarne Gasthuis, Location Haarlem, Department of Radiology and Nuclear Medicine, Haarlem, Netherlands, ³ Northwest Clinics, Location Alkmaar, Department of Neurol- ogy, Alkmaar, Netherlands, ⁵ Amsterdam UMC, Location VUmc, Department of Neurology, Amsterdam, Netherlands, ⁶ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁶ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁷ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC and VUmc, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC and VUmc, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands, ⁸ Amsterdam UMC, Location AMC and VUmc, Department of Radiology & Nuclear Medicine, Amsterdam, Netherlands		
P 008	White matter connectivity networks predict early dementia conversion in Parkinson's disease <u>S.J. Chung^{1, 2}, Y. Kim³, J.H. Jung⁴, H.S. Lee⁵, B.S. Ye², Y.H. Sohn², Y. Jeong⁶, P.H. Lee² ¹Yongin Severance Hospital, Department of Neurology, Yongin-si, Korea, Republic of, ²Yonsei University College of Medicine, Department of Neurology, Seoul, Korea, Republic of, ³Korea Advanced Institute of Science and Technology, Program of Brain and Cognitive Engineering, Daejeon, Korea, Republic of, ⁴Inje University Busan Paik Hospital, Department of Neurology, Busn, Korea, Republic of, ⁵Yonsei University College of Medicine, Biostatistics Collaboration Unit, Seoul, Korea, Republic of, ⁶Korea Advanced Institute of Science and Technology, Department of Bio and Brain Engineering, Daejeon, Korea, Republic of</u>		
P 009 (GPT)	Distinct whole-brain functional connectomics of parkinsonian akinetic-rigid and tremor : a preliminary study in drug-naïve Parkinson's disease <u>H. Wu</u> ¹ , M. Zhang ¹ ¹ The Second Affiliated Hospital, Zhejiang University School of Medicine, Radiology, Hangzhou, China		
P 010	Prediction of Parkinson's disease with dual-phase [18F] FP-CIT PET image through deep learning algorithm <u>SM. Cheon</u> ¹ , Y.J. Jeong ² , DY. Kang ² ¹ Dong-A University College of Medicine, Neurology, Busan, Korea, Republic of, ² Dong-A University College of Medicine, Nuclear Medicine, Busan, Korea, Republic of		
P 011	Association between plasma cytokines and motor, non-motor symptoms in Parkinson's disease <u>K. Abdurakhmonova</u> ¹ , G. Rakhimbaeva ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan		
P 012 (GPT)	Understanding correlation between diffusion MRI-derived white-matter organi- zation and clinical measures in Parkinson's disease patients with freezing of gait <u>V. Mishra</u> ¹ , K. Sreenivasan ¹ , J. Longhurst ² , A. Ritter ¹ , Z. Mari ¹ ¹ Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States, ² Saint Louis University, St Louis, United States		
-------------	--	--	--
P 013	Understanding correlation between diffusion MRI-derived white-matter organ- ization and neuropsychological measures in Parkinson's disease patients with freezing of gait <u>V. Mishra</u> ¹ , K. Sreenivasan ¹ , J. Longhurst ² , J. Caldwell ¹ , A. Ritter ¹ , Z. Mari ¹ ¹ Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States, 2Saint Louis University, St Louis, United States		
P 014 (GPT)	Effects of levodopa on functional connectivity in Parkinson's disease patients with Mild Cognitive Impairment <u>K. Sreenivasan</u> ¹ , X. Zhuang ¹ , A. Ritter ¹ , J. Caldwell ¹ , D. Cordes ¹ , Z. Mari ¹ , V. Mishra ¹ ¹ Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States		
P 015	Tissue biomarker for the detection of dementia with Levi bodies <u>D. Azizova</u> ¹ ¹ Tashkent Medical Academy, Medical Biochemestry, Tashkent, Uzbekistan		
P 016 (GPT)	Gray matter abnormalities in myotonic dystrophy type 1: a voxel-wise meta- analysis <u>Q. Jiang</u> ¹ , J. Lin ¹ , C. Li ¹ , Y. Hou ¹ , H. Shang ¹ ¹ West China Hospital, Sichuan University, Neurology, Chengdu, China		
P 017	Alterations in the HSP70 system in PBMC accompanying Parkinson's disease J. Vavilova ¹ , A. Boyko ¹ , E. Kovalenko ¹ , A. Sapozhnikov ¹ ¹ Shemyakin Ovchinnikov Institute Of Bioorganic Chemistry, Moscow, Russian Federation		
P 018	Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits <u>N. Bohnen</u> ¹ , P. Kanel ¹ , P. Scott ¹ , R. Koeppe ¹ , M. van Emde Boas ¹ , R. Albin ¹ , K. Kerber ¹ , M. Muller ¹		
P 019	¹ University of Michigan, Neurology & Radiology, Ann Arbor, United States The feasibility of using loss of "swallow tail sign" on 3T – susceptibility weighted MRI in diagnosis of Parkinson's disease <u>U.N.L. Ha</u> ¹ , T.V. Nguyen ¹ , K.N.C. Vo ¹ , T.T.H. Dang ¹ , T.N. Tran ¹ ¹ University Medical Center, University of Medicine and Pharmacy Ho Chi Minh City, Ho Chi Minh, Vietnam		
P 020	Features of MRI signs in patients with Parkinson's disease <u>A. Ismatov</u> ¹ , D. Tolibov ¹ , G. Rakhimbaeva ¹ ¹ Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan		
P 021	Correlation specificity of neuroimaging changes with clinic syndromes in Parkinson's disease, vascular parkinsonism and chronic cerebral ischemia SJ. Khamdamov ¹ , D. Akramova ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan		
P 022	The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson's disease across different cognitive status <u>M. Nazmuddin</u> ^{1,2} , T. van Laar ² , P. Zeidman ³ ¹ Dr. Soetomo Teaching Hospital, Faculty of Medicine Airlangga University, Neurology, Surabaya, Indonesi ² University Medical Centre Groningen, University of Groningen, Neurology, Groningen, Netherlands, ³ Well come Centre for Human Neuroimaging, London, United Kingdom		

Topic: Neurosu	rgery (including Deep Brain Stimulation)	
P 024 (GPT	 Reprogramming frequency in clinical practice: 6-months post-implantation of DBS for Parkinson's disease subjects in ADROIT S. Groppa¹, A. Schnitzler², Y. Bezchlibnyk³, J. Pilitsis⁴, C. Giordana⁵, L. Verhagen⁶, M. Frassica⁷, B. Cheeran⁸, SY. Chen⁹ ¹Johannes Gutenberg Universität Mainz, Mainz, Germany, ²Medizinische Einrichtungen der Universität Düsseldorf, Düsseldorf, Germany, ³University of South Florida, Neurology, Tampa, United States, ⁴Albany Medical Center, Albany, United States, ⁵CHU Hopital Pasteur, Nice, France, ⁶Rush University Medical Center, Chicago, United States, ⁷Abbott, Plano, United States, ⁸Abbott, Austin, United States, ⁹Hualien Tzu Chi Hospital, Hualien, Taiwan, Province of China 	
P 025	Deep brain stimulation of posterior subthalamic area for Holmes Tremor <u>H. Kamo</u> ¹ , G. Oyama ^{1,2} , M. Ito ³ , H. Iwamuro ^{4,2} , A. Umemura ^{4,2} , N. Hattori ^{1,2} ¹ Juntendo University School of Medicine, Neurology, Tokyo, Japan, ² Juntendo University Graduate School of Medicine, Research and Therapeutics for Movement Disorders Juntendo University Graduate School of Medicine, Tokyo, Japan, ³ Juntendo University School of Medicine, Psychiatry, Tokyo, Japan, ⁴ Juntendo University School of Medicine, Neurosurgery, Tokyo, Japan	
P 026 (GPT)	Identification of suboptimal response to STN DBS in Parkinson's disease <u>I. Rektor</u> ¹ , M. Bočková ² , E. Výtvarová ³ , M. Lamoš ⁴ , P. Klimeš ⁵ , P. Jurák ⁵ , <u>S. Goldemundová², M. Baláž⁶</u> ¹ Masaryk University, CEITEC and Movements Disorders Centre, Hosp. St. Anne, Brno, Czech Republic, ² Masaryk University, CEITEC and 1st Dept. of Neurology, St. Anne Hosp., Brno, Czech Republic, ³ Masaryk University, Faculty of Informatics, Brno, Czech Republic, ⁴ Masaryk University, CEITEC, Brno, Czech Repub- lic, ⁵ Czech Academy of Sciences, Institute of Scientific Instruments, Brno, Czech Republic, ⁶ Masaryk Uni- versity, CEITEC and Movements Disordesr Centre, Hosp. St. Anne, Brno, Czech Republic	
P 027	 Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease C. Esper¹, A. Merola², <u>L. Himes</u>³, N. Patel⁴, Y. Bezchlibnyk⁵, D. Falconer⁶, D. Weiss⁷, C. Luca⁸, B. Cheeran³, Z. Mari⁹ ¹Emory University School of Medicine, Department of Neurology, Atlanta, United States, ²The Ohio State University Wexner Medical Center, Department of Neurology, Columbus, United States, ³Abbott Neuromodulation, Austin, United States, ⁴Rush University Medical Center, Department of Neurological Sciences, Chicago, United States, ⁵University of South Florida Morsani School of Medicine, Department of Neurosurgery and Brain Repair, Tampa, United States, ⁶Inova Parkinson's and Movement Disorders Center, Alexandria, United States, ⁷Centre for Neurology, Department for Neurodegenerative Disease, and Hertie Institute for Clinical Brain Research, Tübingen, Germany, ⁸University of Miami Miller School of Medicine, Miami, United States, ⁹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States 	
P 028	Hemorrhagic risk in patients who undergo deep brain stimulation on chronic anti- platelet or anticoagulation therapy L. Jackson ¹ , K. Lee ¹ , K. Miller ¹ , B. Klassen ¹ , <u>A. Hassan¹</u> ¹ Mayo Clinic, Rochester, United States	
P 029 (GPT)	Eleven-year outcomes from the deep brain stimulation in early-stage Parkinson's disease pilot clinical trial <u>M. Hacker</u> ¹ , J. Meystedt ¹ , M. Turchan ¹ , K. Harper ¹ , B. Eoff ¹ , K. Cannard ² , R. Fan ¹ , F. Ye ¹ , T. Davis ¹ , P. Konrad ³ , D. Charles ¹ ¹ Vanderbilt University Medical Center, Nashville, United States, ² Walter Reed National Military Medical Center, Bethesda, United States, ³ West Virginia University School of Medicine, Morgantown, United States	
P 030 (GPT)	Improving the accuracy of DBS and other stereotactic neurosurgeries using a 3D-printed skull for preoperative target practice <u>H. Singh</u> ¹ , N. Sawal ² , S. Arjun ³ , M. Matta ³ ¹ Government Medical College and Hospital, Intern, Chandigarh, India, ² Fortis Mohali, Neurology, Mohali, India. ³ Government Medical College and Hospital, Chandigarh, India	

P 031 (GPT)	Clinical milestones demonstrate compression of morbidity in patients with Parkinson's disease treated by deep brain stimulation of the subthalamic nucleus <u>N. Schnalke</u> ¹ , A. Konitsioti ¹ , M. Kurz ¹ , W. Polanski ^{2,2} , P. Themann3, M. Wolz ⁴ , S. Sobottka ² , H. Reichmann ¹ , B. Falkenburger ¹ , L. Klingelhoefer ¹ ¹ Universitätsklinikum Dresden an der Technischen Universität Dresden, Department of Neurology, Dresden, Germany, ² Universitätsklinikum Dresden an der Technischen Universität Dresden, Department of Neurosur- gery, Dresden, Germany, 3Rehabilitationszentrum Niederschoena, Hetzdorf, Germany, 4Klinikum Meißen, Department of Neurology, Meißen, Germany	
P 032	Possible impact of subthalamic deep brain stimulation on glycemic variability and lipid profile in patients with Parkinson's disease J. Samborska-Ćwik ¹ , S. Szlufik ¹ , A. Marszalek ² , D. Koziorowski ¹ ¹ Medical University of Warsaw, Department of Neurology, Warsaw, Poland, ² Medical University of Warsaw, Students' Scientific Association of the Department of Neurology, Warsaw, Poland	
P 033 (GPT)	Compared effects of magnetic-resonance guided ultrasound (MRgFUS) and deep brain stimulation (DBS) in a 58 year old Parkinson's disease patient <u>E. Papić</u> ¹ , V. Komen ² , G. Rožmarić ³ , V. Vuletić ¹ ¹ Faculty of Medicine, University of Rijeka, Department of Neurology, Rijeka, Croatia, ² Clinical Hospital Center Rijeka, Clinic of Neurology, Rijeka, Croatia, ³ Faculty of Medicine, University of Rijeka, Rijeka, Croatia	
P 034	Marked worsening of hypophonia, dysphagia and sialorrhea S/P bilateral STN DBS: a case report. K. Papesh ¹ , J. Nguyen ² , <u>Z. Mari³</u> ¹ Advanced Neurology of Colorado, Movement Disorders, Fort Collins, United States, ² Cleveland Clinic Lou Ruvo Center for Brain Health, Movement Disorders, Las Vegas, United States, ³ Lou Ruvo Center for Brain Health, Movement Disorders, Las Vegas, United States	
P 035	Feasibility of large-scale systematic data collection in a quality improvement registry of deep brain stimulation in Parkinson's disease J. Jimenez-Shahed 1, M. York ² , J. Kirk ³ , A. Berg ⁴ , J. Schwalb ⁵ , M. Siddiqui ⁶ , J. McInerney ⁴ ¹ Icahn School of Medicine at Mount Sinai, New York, United States, ² Baylor College of Medicine, Houston, United States, ³ n/a, Boston, United States, ⁴ Penn State University, Hershey, United States, ⁵ Henry Ford Health System, Detroit, United States, ⁶ Wake Forest School of Medicine, Winston-Salem, United States	
P 036 (GPT)	Subthalamic recordings in chronically implanted parkinsonian patients <u>C. Palmisano</u> 1, I. Hanafi ^{1, 2} , J. Del Vecchio Del Vecchio ^{1,2} , N. Pozzi ¹ , M. Reich ¹ , P. Capetian ¹ , C. Matthies ³ , J. Volkmann ¹ , I.U. Isaias ^{1,2} ¹ University Hospital of Würzburg, Neurology, Würzburg, Germany, ² Julius Maximilian University, Würzburg, Germany, ³ University Hospital of Würzburg, Neurosurgery, Würzburg, Germany	
P 037	Rare neurological indications for Deep Brain Stimulation treatment: experience at the University Medical Center Ljubljana <u>S. Ibrulj</u> ¹ , M. Trošt ¹ , D. Flisar ¹ , M. Benedičič ² , D. Georgiev ¹ ¹ University Medical Center Ljubljana, Department of Neurology, Ljubljana, Slovenia, ² University Medical Center Ljubljana, Department of Neurosurgery, Ljubljana, Slovenia	
P 038	An experimental paradigm for testing effect of alternating-frequency deep brain stimulation on gait, in Parkinson disease J. Liao ¹ , R. Kaya ¹ , J. Yu ¹ , M. Koop ² , A. Rosenfeldt ² , J. Alberts ² , K. Baker ³ , H. Fernandez ¹ ¹ Cleveland Clinic Neurological Institute, Cleveland, United States, ² Cleveland Clinic Lerner Research Insti- tute, Biomedical Engineering, Cleveland, United States, ³ Cleveland Clinic Lerner Research Institute, Neuro- sciences, Cleveland, United States	

P 039 (GPT)	 STN DBS improves balance disorders in Parkinson's disease patients and impacts the disease progression <u>S. Szlufik</u>¹, M. Kloda¹, I. Potrzebowska¹, K. Jaros², A. Gędek², A. Przybyszewski³, T. Mandat⁴, D. Koziorowski¹ ¹Medical University of Warsaw, Department of Neurology, Faculty of Health Sciences, Warszawa, Poland, ²Medical University of Warsaw, Department of Neurology, Students' Scientific Group, Faculty of Health Science, Warszawa, Poland, ³Polish Japanese Academy of Information Technology, Department of Informatics, Warsaw, Poland, ⁴Maria Sklodowska Curie Memorial Oncology Center, Department of Neurosurgery, Warsaw, Poland 	
P 040	 ¿It Is Any Difference Between Directional Vs Omnidirectional Lead For Treatment I Parkinson Disease? <u>O. Bernal-Pacheco</u>^{1,2}, M. Fonseca Ramos³ ¹Universidad Militar Nueva Granada, Neurology, Bogotá, Colombia, ²Instituto Ortopedico Roosevelt, Neuro ogy, Bogota, Colombia, ³Instituto Ortopedico Roosevelt, Neurology, Bogotá, Colombia 	
Topic: Behavior,	Cognition, Psychiatry	
P 041 (GPT)	Clinical evaluation of neuropsychiatric symptoms in patients with Parkinson's disease during COVID-19 pandemic: risk factors <u>M. Salokhiddinov</u> ¹ , R. Nuriddinov ¹ ¹ Zangiota №2 Republic COVID Specialised Center, Zangiota, Uzbekistan	
P 042	Homologs and order of duplication of insulin-like growth factor in humans <u>A. Venger</u> ¹ , O. Venger ² ¹ Odessa National Medical University, Department of Microbiology, Virology and Immunology, Odesa, Ukraine, ² State institution 'South Ukrainian National Pedagogical University named after K. D. Ushynsky', Department of General Disciplines and Clinical Medicine, Odesa, Ukraine	
P 043	Paralogs and order of duplication of serotonin 1A receptor in humans <u>O. Venger</u> ¹ , A. Venger ² ¹ State Institution 'South Ukrainian National Pedagogical University named after K. D. Ushynsky', Depar ment of General Disciplines and Clinical Medicine, Odesa, Ukraine, ² Odessa National Medical University Department of Microbiology, Virology and Immunology, Odesa, Ukraine	
P 044	Evaluation of the adaptive capacity of patients with Prakinson's disease <u>S. Djalilova</u> ¹ ¹ Tashkent Medical Academy, Neurology and Medical Psychology, Tashkent, Uzbekistan	
P 045	Non-permitted food colorants induced cognitive impairment and neurotoxicity in hippocampus of rats <u>P. Biswas</u> ¹ , D. Bose ¹ , R.S. Yadav ¹ ¹ Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar – 470003 (MP), India, Department of Criminology & Forensic Science, School of Applied Sciences, Sagar, India	
P 046	Correlation between NREM Sleep EEG characteristics and Mild Cognitive Impair- ment in patients with Parkinson's disease <u>K. Abdurakhmonova</u> ¹ , G. Rakhimbaeva ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan	
P 047 (GPT)	The role of dopaminergic therapy on cognition in Parkinson's disease <u>L. Montaser Kouhsari</u> ¹ , A. Bakkou ^{r2} , D. Shohamy ^{3,4} ¹ Stanford University, Neurology, Palo Alto, United States, ² University of Chicago, Psychology, Chicago, United States, ³ Columbia University/ The Mortimer Zuckerman Mind Brain Behavior Institute, Psychology, New York, United States, ⁴ Columbia University Zuckerman Institute, Psychology, New York, United States	

P 049	 Early onset dementia with parkinsonism in a patient with pathogenic mutations in CSF1R and ABCD1 gene G. Novotni¹, N. Tanovska², I. Barbov³, F. Stojkovska³, V. Aleksovski³, K. Karanfilovik³, M. Pendaroska³, D. Stoilkovski³, A. Jovkovska Gerasovska³, A. Angelova³, K. Aleksovska³, S. Hasani³, D. Plasheska Karanfilska⁴, A. Novotni⁵ ¹University Ss Cyril and Methodius, Medical Faculty, University Clinic of Neurology, Neuroimmunology, Dementia Outpatient Clinic, Skopje, North Macedonia, The Republic of, ²University Ss Cyril and Methodius, Medical Faculty, University Clinic of Neurology, Skopje, North Macedonia, The Republic of, ³University Ss Cyril and Methodius, Medical Faculty, University Clinic of Neurology, Skopje, North Macedonia, The Republic of, ⁴Macedonian Academy of Sciences and Arts, Genetic Laboratory 'Prof. Georgi Efremov', Skopje, North Macedonia, The Republic of, ⁵University Ss Cyril and Methodius, Medical Faculty, University Clinic of Psychiatry, Skopje, North Macedonia, The Republic of 	
P 050	 Brain atrophy correlates with neuropsychological examination in Parkinson's disease patients <u>S. Szlufik</u>¹, K. Duszynska-Was¹, K. Szalata², P. Romaniuk², M. Karolak², A. Drzewinska¹, D. Koziorowski¹ ¹Medical University of Warsaw, Department of Neurology, Faculty of Health Sciences, Warszawa, Poland, ²Medical University of Warsaw, Department of Neurology, Students' Scientific Group, Faculty of Health Science, Warszawa, Poland 	
Topic: Parkinsor	n Disease: Genetics	
P 051 (GPT)	 Polygenic resilience inheritance modulates the penetrance of Parkinson's disease genetic risk factors <u>H. LIU</u>¹, M. Dehestani¹, C. Blauwendraat², M.B. Makarious², H. Leonard², J.J Kim², C. Schulte¹, A. Noyce³, B.M Jacobs³, I. Foote³, M. Sharma⁴, M. Nalls², A. Singleton², T. Gasser¹, S. Bandres-Ciga² ¹Hertie Institute, Neurodegeneration Department, Tuebingen, Germany, ²National Institutes of Health, Laboratory of Neurogenetics, Molecular Genetics Section, National Institute on Aging, Bethesda, United States, ³Queen Mary University of London, London, London, United Kingdom, ⁴Institute for Clinical Epidemiology and Functional Biometry, University of Tuebingen, Tuebingen, Germany 	
P 052	Autophagy-lysosomal and mitochondrial polygenic risk scores in Parkinson's disease <u>M. Dehestani</u> ¹ , H. Liu ¹ , C. Schulte ¹ , V. Bansal ² , T. Gasser ¹ ¹ Hertie Institute for Clinical Brain Research, University of Tuebingen, Department of Neurodegenerative Disease, Tuebingen, Germany, ² German Center for Neurodegenerative Disease DZNE, Tuebingen, German	
P 053 (GPT)	Diagnostic utility of whole-exome sequencing in early onset and familial Parkin- son's disease: Preliminary findings in a regional centre study <u>V. Rački</u> ^{1,2} , M. Hero ^{1,2} , G. Rožmarić ³ , V. Vuletić ^{1,2} ¹ Faculty of Medicine, University of Rijeka, Department of Neurology, Rijeka, Croatia, ² Clinical Hospital Center Rijeka, Clinic of Neurology, Rijeka, Croatia, ³ Faculty of Medicine, University of Rijeka, Rijeka, Croa	
P 054	Biomarkers of Parkinson's disease <u>A. Kondybayeva</u> ¹ , A. Aralbayeva ² , S. Kamenova ¹ , A. Akimniyazova ¹ , A. Pyrkova ³ , A. Ivashchenko ³ , K. Kuzhybayeva ¹ ¹ AI-Farabi Kazakh National University, Faculty of Medicine and Health Care, Almaty, Kazakhstan, ² Asfendi- yarov Kazakh National Medical University, Neurology, Almaty, Kazakhstan, ³ AI-Farabi Kazakh National University, Faculty of Biology and Biotechnology, Almaty, Kazakhstan	

P 055 (GPT)	PLA2G6-associated neurodegeneration in three different populations-case series L. Milanowski ^{1,2} , R. Hanna AL-Shaikh ² , V. Holla ³ , K. Kurihara ⁴ , R. Yadav ³ , N. Kamble ³ , B. Muthusamy ⁵ , D. Koziorowski ¹ , S. Szlufik ¹ , D. Hoffman-Zacharska ⁶ , S. Fujioka ⁴ , O.A. Ross ⁷ , K. Wierenga ⁸ , Z.K. Wszolek ² , P.K. Pal ³ ¹ Medical University of Warsaw, Faculty of Health Science, Department of Neurology, Warsaw, Poland, ² Mayo Clinic, Department of Neurology, Jacksonville, United States, ³ National Institute of Mental Health & Neurosciences, Department of Neurology, Bengaluru, India, ⁴ Fukuoka University, Department of Neurology, Fukuoka, Japan, ⁵ Bengaluru, India and Manipal Academy of Higher Education, Institute of Bioinformatics, Manipal, India, ⁶ Institute of Mother and Child, Department of Medical Genetics, Warsaw, Poland, ⁷ Mayo Clinic, Department of Neuroscience, Jacksonville, United States, ⁸ Mayo Clinic, Department of Clinical		
()	Genomics, Jacksonville, United States		
P 056 (GPT)	Plasma miR-153 and miR-223 levels as potential biomarkers in Parkinson's disease <u>W. Chen</u> ¹ ¹ Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Department of Neurology, Shanghai, China		
P 057	Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis J. Huang ¹ , Y. Cheng ¹ , C. Li ¹ , H. Shang ¹ ¹ West China Hospital, Sichuan University, Department of Neurology, Laboratory of Neurodegenerative Disorders, Bare Diseases Center, National Clinical Pasearch Center for Geriatrics, Chengdy, China		
P 058	On the question of genetic predisposition to Parkinson's disease <u>K. Daminova</u> ¹ , D. Akramova ^{1,1} 'Tashkent Medical Academy, Tashkent, Uzbekistan		
P 059	Parkin gene may rescue mitochondrial dysfunction induced by FUS expression in Drosophila <u>E.J. Choi</u> ¹ , S.J. Cha ² , D.G. Lee ³ , K. Kim ⁴ ¹ Soonchunhyang University, Gumi Hospital, Neurology, Gumi, Korea, Republic of, ² Soonchunhyang Univer- sity, Department of Medical Biotechnology, Asan, Korea, Republic of, ³ UBC Faculty of Medicine, Vancouver, Canada, ⁴ Soonchunhyang University, Medical Biotechnology, Asan, Korea, Republic of		
P 060 (GPT)	Heads - It's Parkinson's; tails - it's cancer, a kindred of Parkinsonism and Malignan-		
	<u>M. Matta</u> ¹ , H. Singh ¹ , N. Sawal ² , S. Arjun ¹ 1Government Medical College and Hospital, Chandigarh, India, 2Fortis Mohali, Neurology, Mohali, India		
P 061 (GPT)	Green tea intake and Parkinson's disease progression: a Mendelian randomization study <u>C. Li</u> ¹ , J. Lin ¹ , T. Yang ¹ , H. Shang ¹ ¹ West China Hospital Sichuan University, Neurology, Chengdu, China		
P 062 (GPT)	 Genomic analyses of a large Swedish multi-incident kindred with autosomal dominant Parkinson's disease with dementia E. Ygland Rödström¹, A. Soto-Beasley², E. Englund³, E. Kafantari¹, D.W. Dickson², Z.K. Wszolek⁴, A. Puschmann⁵, O.A. Ross⁶ ¹Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden ²Mayo Clinic, Department of Neuroscience, Jacksonville, United States, ³Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden, ⁴Mayo Clinic, Department of Neurology, Lund, Sweden, ⁶Mayo Clinic, Department of Neuroscience, Department of Clinical Sciences & Mayo Graduate School Neuroscience Track Jacksonville, United States 		
P 063	Leucine-rich repeat kinase2 (LRRK2) associated Parkinson's disease: less vulnerable during Covid-19 pandemic? <u>A. Gharbi</u> ¹ , I. Kacem ^{1,2} , I. Sghaier1, S. Mrabet ^{1,2} , A. Souissi ¹ , A. Gargouri ^{1,2} , A. Nasri ^{1,2} , R. Gouider ^{1,2} ¹ Razi University Hospital, Department of Neurology, LR18SP03, Manouba, Tunisia, ² Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia		

P 065	Exploration of the Immune-related genes Signatures and potential Molecular Mechanisms shared between AD and PD <u>k. zhou</u> ¹ , y. song ² , l. jin ³ ¹ Tongji University, Department of Neurology, Tongji Hospital, School of Medicine, shanghai, China, ² Tong- ji University, Fundamental Research Center, Department of Neurology and Neurological Rehabilitation, Shanghai Yangzhi Rehabilitation Hospital, School of Medicine, shanghai, China, ³ Tongji University, Fun- damental Research Center, Department of Neurology and Neurological Rehabilitation, Shanghai Yangzhi Rehabilitation Hospital, School of Medicine;, shanghai, China		
P 066 (GPT)	Charcot-Marie-Tooth Disease associated with Parkinson Disease, about a case <u>H. Pacheco Mendoza</u> ¹ , V. Alvarez Rivera ¹ ¹ Universidad Nacional Autonoma de Mexico, Mexico City, Mexico		
Topic: Parkinsor	n Disease: Subtypes, natural course		
P 067	Relationship between risk and protective factors and clinical features of Parkinson's disease <u>M. Costanzo¹</u> , D. Belvisi ² , R. Pellicciari ³ , A. Fabbrini ² , G. Ressa ⁴ , S. Pietracupa ¹ , M. De Lucia ¹ , N. Modugno ¹ , F. Magrinelli ⁵ , C. Dallocchio ⁶ , T. Ercoli ⁷ , A. Nicoletti ⁸ , M. Zappia ⁸ , P. Solla ⁷ , M. Bologna ² , G. Fabbrini ² , M. Tinazzi ⁵ , A. Conte ² , A. Berardelli ² , G. Defazio ⁷ ¹ IRCCS Neuromed, Pozzilli, Italy, ² Sapienza, University of Rome, Department of Human Neurosciences,		
	Rome, Italy, ³ "Aldo Moro" University of Bari, Department of Basic Medical Sciences, Bari, Italy, ⁴ Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, New York, United States, ⁵ University of Verona, Department of Neurosciences, Verona, Italy, ⁶ ASST Pavia-Ospedale Civile di Voghera, Voghera, Italy, ⁷ University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italy, ⁸ University of Catania, Department G.F. Ingrassia, Catania, Italy		
P 068 (GPT)	Amantadine treatment in Parkinson's disease patients as a modulatory factor of SARS-Cov-2 infection <u>S. Szlufik</u> ¹ , A. Chudzik ² , A. Przybyszewski ² , D. Koziorowski ¹ ¹ Medical University of Warsaw, Department of Neurology, Faculty of Health Sciences, Warszawa, Poland, ² Polish Japanese Academy of Information Technology, Department of Informatics, Warsaw, Poland		
Topic: Parkinsor	n Disease: Clinical assessment (including devices)		
P 069	Effect of ventricular metrics on the treatment response in Parkinson's disease <u>JJ. Lee</u> ¹ , J.S. Baik ² ¹ IIsan Paik Hospital, Inje University College of Medicine, Department of Neurology, Goyang, Korea, Rep lic of, ² Sanggye Paik Hospital, Inje University College of Medicine, Department of Neurology, Seoul, Kor Republic of		
P 070	Continuous wavelet transforms to improve the accuracy of motor assessments o Parkinson's disease <u>T. Kosuri</u> ¹		
P 071 (GPT)	Prevalence and associated factors of malnutrition in patients with Parkinson's disease using CONUT and GNRI <u>Z. Jiang</u> ¹ , R. Ou ¹ , Y. Chen ¹ , L. Zhang ¹ , Q. Wei ¹ , Y. Hou ¹ , X. Gu ¹ , B. Cao ¹ , K. Liu ¹ , H. Shang ¹ , W. Song ¹ ¹ Sichuan University, Department of Neurology, West China Hospital, Chengdu, China		
P 072	Characteristic of impulse control disorders in Polish patients with Parkinson's disease <u>M. Toś</u> ¹ , J. Siuda ¹ , A. Grażyńska ² ¹ Medical University of Silesia, Department of Neurology, Katowice, Poland, ² Medical University of Si Department of Radiology and Nuclear Medicine, Katowice, Poland		

P 074 (GPT)	Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems <u>M. Sapmaz Atalar</u> ^{1,2} , Ş.N. Oğur ² , G. Genç ³ ¹ Bahçeşehir University, Neuroscience, İstanbul, Turkey, ² University of Health Sciences, Speech and Lan- guage Therapy, İstanbul, Turkey, ³ University of Health Sciences, Şişli Etfal Training and Research Hospital, Neurology, Istanbul, Turkey
P 075	Reliability and validity study of a Turkish version of the Sialorrhea Clinical Scale for Parkinson's disease (SCS-TR) <u>M. Sapmaz Atalar</u> ^{1,2} , G. Genç ³ ¹ Bahçeşehir Universty, Neuroscience, İstanbul, Turkey, ² University of Health Sciences, Speech and Lan- guage Therapy, İstanbul, Turkey, ³ University of Health Sciences, Şişli Etfal Training and Research Hospital, Neurology, Istanbul, Turkey
P 076	Utilizing technology-based outcome measures in the natural setting to answer intriguing clinical questions in Parkinson disease <u>O. Phillips</u> ¹ , P. Salles ² , J. Liao ¹ , J. Yu ¹ , H. Fernandez ¹ ¹ Cleveland Clinic, Center for Neurological Restoration, Cleveland, United States, ² Centro de Trastornos del Movimiento, Santiago, Chile
P 077	Application of the Chinese version of the Montreal cognitive assessment-basic for assessing Mild Cognitive Impairment in Parkinson's disease <u>W. Chen¹</u> ¹ Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Department of Neurology, Shanghai, China
P 078	REM sleep behavior disorder correlates with constipation in de novo Chinese Parkinson's disease patients <u>Y. Chen</u> ¹ , Q. Xu ¹ , L. Wu ¹ , M. Zhou ¹ , Y. Lin ¹ , Y. Jiang ¹ , Q. He ¹ , L. Zhao ¹ , Y. Dong ¹ , J. Liu ¹ , W. Chen ¹ ¹ Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Department of Neurology, Shanghai, China
P 079 (GPT)	Comparison of autonomic dysfunction in essential tremor and Parkinson's disease: a pilot study <u>J. Malkiewicz</u> ¹ , J. Siuda ¹ ¹ Medical University of Silesia, Department of Neurology, School of Medicine, Katowice, Poland
P 080	Preliminary verification of a Kinect-based system for evaluating postural abnormalities in patients with Parkinson's disease <u>R. Hong</u> ¹ , Z. Wu ¹ , T. Zhang ¹ , Z. Zhang ¹ , A. Lin ¹ , X. Su ² , Y. Jin ² , Y. Gao ² , K. Peng ¹ , L. Li ¹ , L. Pan ¹ , H. Zhi ² , Q. Guan ¹ , L. Jin ^{3,1,4} ¹ Tongji University, Neurological Department, Tongji Hospital, Shanghai, China, ² IFLYTEK Suzhou Research Institute, Suzhou, China, ³ Tongji University, Department of Neurology and Neurological Rehabilitation, Shanghai, China, ⁴ Shanghai Clinical Research Center for Aging and Medicine, Shanghai, China
P 081	A novel summary index derived from Kinect to evaluate the severity of postural abnormalities in patients with Parkinson's Disease <u>R. Hong</u> ¹ , T. Zhang ¹ , Z. Zhang ¹ , Z. Wu ¹ , A. Lin ¹ , X. Su ² , Y. Jin ² , Y. Gao ² , K. Peng ¹ , L. Li ¹ , L. Pan ¹ , H. Zhi ² , Q. Guan ¹ , L. Jin ^{3,1,4} 'Tongji University, Neurological Department, Tongji Hospital, Shanghai, China, ² IFLYTEK Suzhou Research Institute, Suzhou, China, ³ Tongji University, Department of Neurology and Neurological Rehabilitation, Shanghai, China, ⁴ Shanghai Clinical Research Center for Aging and Medicine, Shanghai, China
P 082	Assessment of pain syndrome in Parkinson's disease in Uzbekistan <u>G. Goyibova</u> ¹ , G. Rakhimbaeva ² , K. Sobitjon ² ¹ Tashkent Pediatric Medical Institute, Department of Neurology, Tashkent, Uzbekistan, ² Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan
P 083	Real-world, digital sleep biomarkers capture of Parkinson's disease impact <u>J.H. Chang</u> ¹ , D. Bhatti ¹ , T. Mieth ¹ , A. Tartaglia ¹ , M. Rizzo ¹ , J. Bertoni ¹ , J. Merickel ¹ ¹ University of Nebraska Medical Center, Neurological Sciences, Omaha, United States

P 084	Olfactory dysfunction and severity of tremor – is there a connection? <u>D.D. Pokhabov</u> ^{1,2} , V. Abramov ² , M. Sadovsky ¹ , D.V. Pokhabov ^{1,2} ¹ Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation, ² Federal Siberian Research Clini- cal Center, Department of Neurological Diseases, Krasnoyarsk, Russian Federation	
P 086	The impact of non motor symptoms on quality of life in patients with young onset Parkinson's disease <u>K. Abdurakhmonova</u> ¹ , G. Rakhimbaeva ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan	
P 087	Evaluation of extrapyramidal diseases with Parkinson's disease in patients suffer- ing from stroke in Tashkent region, Uzbekistan J. Sabirov ¹ , U. Azamat ¹ , R. Yuldashev ¹ ¹ Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan	
P 088	Clinical correlations of Parkinson's disease and vascular parkinsonism: a retrospective review from Uzbekistan <u>A. Umarov</u> ¹ , S. Kuranbaeva ¹ , G. Goyibova ² ¹ Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan, ² Tashkent Pediatric Medical Institute, Department of Neurology, Tashkent. Uzbekistan	
P 089 (GPT)	Correlation between age and positive and negative affect in Parkinson's disease A. Almaraz-Espinoza ¹ , A. Banegas-Lagosa ¹ , <u>E. Robles</u> ¹ , P. Bazan-Rodriguez ² , E.S. Velazquez-Ávila ¹ , A. González-Cantú ³ , A. Cervantes-Arriaga ² , M. Rodriguez-Violante ² , D. Martinez-Ramirez ¹ ¹ Tecnológico de Monterrey, Monterrey, Mexico, ² Laboratorio Clinico de Enfermedades Degenerativas, Insti- tuto Nacional de Neurologia y Neurocirugia, Ciudad de Mexico, Mexico, ³ Christus Muguerza Alta Especiali- dad, Monterrey, Mexico	
P 091	Validation of patient administered psychosis questionnaire for screening Parkinson's disease patients for psychosis. <u>V. Koneru</u> ¹ , A. Cole ² , K. Crist ³ , A. Espay ⁴ , D. Weintraub ⁵ , W. Ondo ¹ ¹ Houston Methodist Neurological Institute, Neurology, Movement Disorders, Houston, United States, ² University of Texas at Austin, Steve Hicks School of Social Work, Austin, Texas, United States, ³ Houston Area Parkinson Society, Executive Directo, Houston, Texas, United States, ⁴ University of Cincinnati Gardner Neuroscience Institute, Neurology, Movement Disorders, Cincinnati, Ohio, United States, ⁵ University of Pennsylvania, Psychiatry, Philadelphia, PA, United States	
Topic: Parkinsor	n Disease: Therapy (excluding surgical, physical)	
P 092	Long-term motor and non-motor symptom benefits in patients with advanced Parkinson's disease treated with Levodopa-Carbidopa Intestinal Gel: DUOGLOBE final analysis K.R. Chaudhuri ¹ , N. Kovács ² , F.E Pontieri ³ , J. Aldred ⁴ , P. Bourgeois ⁵ , T.L Davis ⁶ , E. Cubo ⁷ ,	
	M. Anca-Herschkovitsch ⁸ , R. Iansek ⁹ , M.S Siddiqui ¹⁰ , M. Simu ¹¹ , L. Bergmann ¹² , P. Kukreia ¹² , O. Ladhapi ¹² , J. Jia ¹² , D.G. Standaert ¹³	
	¹ Parkinson's Foundation International Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Biomedical Research Centre, Psychology & Neuroscience, London, United Kingdom, ² University of Pécs, Department of Neurology, Pécs, Hungary, ³ Sapienza University of Rome, Department of Neurological Sciences, Mental Health & Sensory Organs, Rome, Italy, ⁴ Selkirk Neurology, Spokane, United States, ⁵ AZ Groeninge, Department of Neurology, Kortrijk, Belgium, ⁶ Vanderbilt University Medical Center, Department of Neurology, Nashville, United States, ⁷ Hospital Universitario Burgos, Neurology Department, Burgos, Spain, ⁸ Edith Wolfson Medical Center, Department of Neurology, Holon, Israel, ⁹ Kingston Centre, Monash Health, Melbourne, Australia, ¹⁰ Wake Forest School of Medicine, Department of Neurology, Win- ston Salem, United States, ¹¹ Victor Babes University of Medicine and Pharmacy, Department of Neurology, Timisoara, Romania, ¹² AbbVie Inc., North Chicago, United States, ¹³ University of Alabama at Birmingham, Department of Neurology, Birmingham, United States	

P 093	Design of the Remote Optimization Adjustment and Measurement for Deep Brain Stimulation (ROAM-DBS) randomized prospective outcomes study of remote programming <u>T. Tomlinson¹</u> , M. Feldman ² , A. Gharabaghi ³ , S. Groppa ⁴ , L. Luo ⁵ , H. Lu ⁶ , C. Luca ⁷ ,
	V. Marshall ⁸ , A. Merola ⁹ , A. Schnitzler ¹⁰ , L. Verhagen ¹¹ , B. Walter ¹² , C. Wu ¹³ ,
	S.E. Zauber ¹⁴ , B. Cheeran ¹
	¹ Abbott Laboratories, Neuromodulation, Plano, United States, ² Dartmouth-Hitchcock Medical Center, Neurol-
	ogy, Lebanon, United States, ³ Institute for Neuromodulation and Neurotechnology, Eberhard Karls University
	of Tuebingen, Neurosurgery and Neurotechnology, Tuebingen, Germany, ⁴University Medical Center of the
	Johannes Gutenberg-University Mainz, Section of Movement Disorders and Neurostimulation, Biomedical
	Statistics and Multimodal Signal Processing Unit, Department of Neurology, Focus Program Translational
	Neuroscience, Mainz, Germany, ⁵Beth Israel Deaconess Medical Center, Neurology, Boston, United States,
	⁶ Swedish Health System, Seattle, United States, ⁷ University of Miami Miller School of Medicine, Neurology,
	Maimi, United States, ⁸ Queen Elizabeth University, Neurology, Glasgow, United Kingdom, ⁹ The Ohio State
	University Wexner Medical Center, Madden Center for Parkinson Disease and Other Movement Disorders,
	Department of Neurology, Colombus, United States, ¹⁰ Heinrich-Heine-Universität Düsseldorf, Institute of Clin-
	ical Neuroscience and Medical Psychology, Düsseldorf, Germany, ¹¹ Rush University, Neurological Sciences,

Center, Cleveland, United States, ¹³Thomas Jefferson University, Neurosurgery, Philadelphia, United States, ¹⁴Indiana University School of Medicine, Neurology, Indianapolis, United States P 094 (GPT) Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for treatment of Parkinson disease R.R. Walsh¹, S.P. Piccoli¹, R.S. Talluri¹, S. Mandhane¹, D. Love¹, O. Hurko¹, S.-L. Yao¹, V. Ramanathan¹, N. Damle¹

Chicago, United States, ¹²University Hospitals Cleveland Medical Center, Parkinson's & Movement Disorders

¹Sun Pharma Advanced Research Company (SPARC), Neurology, Princeton, United States P 095 Local field potential and clinical symptoms of Parkinson's disease patients implanted with adaptive deep brain stimulation G. Oyama¹, H. Kamo¹, M. Ito², H. Iwamuro³, A. Umemura³, N. Hattori¹ ¹Juntendo University, Neurology, Tokyo, Japan, ²Juntendo University, Psychiatry, Tokyo, Japan, ³Juntendo University, Neurosurgery, Tokyo, Japan

P 096 Efficacy of incobotulinumtoxinA in subjects with sialorrhea, assessed using the modified Radboud Oral Motor inventory for Parkinson's disease (mROMP) W. Jost¹, O. Michel², C. Oehlwein³, J. Slawek⁴, A. Bogucki⁵, S. Ochudlo⁶, M. Banach⁷, F. Pagan⁸, B. Flatau-Baqué⁹, J. Csikós⁹, A. Blitzer¹⁰ ¹Parkinson-Klinik, Ortenau, Baden-Württemberg, Germany, ²University Hospital Brussels, Brussels, Belgium, ³Neurological Outpatient Clinic for Parkinson Disease and Deep Brain Stimulation, Gera, Germany, ⁴Medical University of Gdansk, Gdansk, Poland, ⁵Medical University of Łódź, Łódź, Poland, ⁶Medical University of Silesia, Katowice, Poland, ⁷Collegium Medicum, Jagiellonian University, Krakow, Poland, ⁸Georgetown University, Washington D.C., United States, 9Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany, 10 Icahn School of Medicine at Mt. Sinai, New York, United States

46

P 097 (GPT)	Real-world effect of age on long-term effectiveness and safety of levodopa- carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study <i>M. Simu</i> ¹ , K.R. Chaudhuri ² , N. Kovács ³ , F.E Pontieri ⁴ , J. Aldred ⁵ , P. Bourgeois ⁶ , <i>T.L Davis</i> ⁷ , M. Anca-Herschkovitsch ⁸ , R. Iansek ⁹ , M.S Siddiqui ¹⁰ , L. Bergmann ¹¹ , O. Ladhani ¹¹ , T. Gao ¹¹ , D.G Standaert ¹² , E. Cubo ¹³ ¹ Victor Babes University of Medicine and Pharmacy, Department of Neurology, Timisoara, Romania, ² Parkinson's Foundation International Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Biomedical Research Centre, Psychology & Neuroscience, London, United Kingdom, ³ University of Pécs, Department of Neurology, Pécs, Hungary, ⁴ Sapienza University of Rome, Department of Neurological Sciences, Mental Health & Sensory Organs, Rome, Italy, ⁵ Selkirk Neurology, Spokane, United States, ⁶ AZ Groeninge, Department of Neurology, Kortrijk, Belgium, ⁷ Vanderbilt University Medical Center, Department of Neurology, Nashville, United States, ⁸ Edith Wolfson Medical Center, Department of Neurol- ogy, Holon, Israel, ⁹ Kingston Centre, Monash Health, Melbourne, Australia, ¹⁰ Wake Forest School of Medi- cine, Department of Neurology, Winston Salem, United States, ¹¹ AbbVie Inc., North Chicago, United States, ¹² University of Alabama at Birmingham, Department of Neurology, Birmingham, United States, ¹³ Hospital Universitario Burgos, Neurology Department, Burgos, Spain
P 098	Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and
	<u>W. Jost</u> ¹ , A. Friedman ² , O. Michel ³ , C. Oehlwein ⁴ , J. Slawek ⁵ , A. Bogucki ⁶ , S. Ochudlo ⁷ , M. Banach ⁸ , F. Pagan ⁹ , B. Flatau-Baque ¹⁰ , U. Dorsch ¹⁰ , J. Csikos ¹⁰ , A. Blitzer ¹¹ ¹ Parkinson-Klinik, Ortenau, Wolfach, Germany, ² Medical University of Warsaw, Warsaw, Poland, ³ University Hospital Brussels, Brussels, Belgium, ⁴ Neurological Outpatient Clinic for Parkinson Disease and Deep Brain Stimulation, Gera, Germany, ⁵ Medical University of Gdansk, Gdansk, Poland, ⁶ Medical University of Łódź, Łódź, Poland, ⁷ Medical University of Silesia, Katowice, Poland, ⁸ Jagiellonian University Medical College, Krakow, Poland, ⁹ Georgetown University, Washington D.C., United States, ¹⁰ Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany, ¹¹ Icahn School of Medicine at Mt. Sinai, New York, United States
P 099	Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson's disease and other neurologic conditions <u>W. Jost</u> ¹ , F. Pagan ² , A. Friedman ³ , O. Michel ⁴ , C. Oehlwein ⁵ , J. Slawek ⁶ , A. Bogucki ⁷ , S. Ochudlo ⁸ , M. Banach ⁹ , B. Flatau-Baqué ¹⁰ , J. Csikos ¹⁰ , A. Blitzer ¹¹ ¹ Parkinson-Klinik, Ortenau, Wolfach, Germany, ² Georgetown University, Washington D.C., United States, ³ Med- ical University of Warsaw, Warsaw, Poland, ⁴ University Hospital Brussels, Brussels, Belgium, ⁵ Neurological Outpatient Clinic for Parkinson Disease and Deep Brain Stimulation, Gera, Germany, ⁶ Medical University of Gdansk, Gdansk, Poland, ⁷ Medical University of Łódź, Łódź, Poland, ⁸ Medical University of Silesia, Katowice, Poland, ⁹ Collegium Medicum, Jagiellonian University, Krakow, Poland, ¹⁰ Merz Pharmaceuticals GmbH, Frank- furt am Main, Germany, ¹¹ Icahn School of Medicine at Mt. Sinai, New York, United States
P 100	Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for
	<u>W. Jost¹</u> , A. Friedman ² , O. Michel ³ , C. Oehlwein ⁴ , J. Slawek ⁵ , A. Bogucki ⁶ , S. Ochudlo ⁷ , M. Banach ⁸ , F. Pagan ⁹ , B. Flatau-Baqué ¹⁰ , J. Csikos ¹⁰ , C.J. Cairney ¹¹ , A. Blitzer ¹² ¹ Parkinson-Klinik, Ortenau, Wolfach, Germany, ² Medical University of Warsaw, Warsaw, Poland, ³ University Hospital Brussels, Brussels, Belgium, ⁴ Neurological Outpatient Clinic for Parkinson Disease and Deep Brain Stimulation, Gera, Germany, ⁵ Medical University of Gdansk, Gdansk, Poland, ⁶ Medical University of Łódź, Łódź, Poland, ⁷ Medical University of Silesia, Katowice, Poland, ⁸ Collegium Medicum, Jagiellonian University, Krakow, Poland, ⁹ Georgetown University, Washington D.C., United States, ¹⁰ Merz Pharmaceu- ticals GmbH, Frankfurt am Main, Germany, ¹¹ CMC - McCann, Glasgow, United Kingdom, ¹² Icahn School of Medicine at Mount Sinai, New York, United States

Ρ	101

P 101	 Long-term motor and non-motor symptom benefits of levodopa-carbidopa intestinal gel by baseline Hoehn & Yahr stage: DUOGLOBE post hoc analysis <i>F.E Pontieri</i>¹, K.R. Chaudhuri², J. Aldred³, P. Bourgeois⁴, T.L Davis⁵, E. Cubo⁶, M. Anca-Herschkovitsch⁷, R. Iansek⁸, M.S Siddiqui⁹, M. Simu¹⁰, L. Bergmann¹¹, O. Ladhani¹¹, T. Gao¹¹, D.G Standaer¹¹², N. Kovács¹³ 'Sapienza University of Rome, Department of Neurological Sciences, Mental Health & Sensory Organs, Rome, Italy, ²Parkinson's Foundation International Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Biomedical Research Centre, Psychology & Neuroscience, London, United Kingdom, ³Selkirk Neurology, Spokane, United States, ⁴AZ Groeninge, Department of Neurology, Kortrijk, Belgium, ⁵Vanderbilt University Medical Center, Department of Neurology, Nashville, United States, ⁶Hospital Universitario Burgos, Neurology Department, Burgos, Spain, ⁷Edith Wolfson Medical Center, Department of Neurology, Holon, Israel, ⁸Kingston Centre, Monash Health, Melbourne, Australia, ⁹Wake Forest School of Medicine, Department of Neurology, Timisoara, Romania, ¹¹AbbVie Inc., North Chicago, United States, ¹²University of Alabama at Birmingham, Department of Neurology, Birmingham, United States,
	¹³ University of Pécs, Department of Neurology, Pécs, Hungary
P 102 (GPT)	Levodopa-Carbidopa intestinal gel may improve treatment-resistant freezing of gait <u>M. Shackleford^{1,2}</u> , V. Mishra ² , Z. Mari ² ¹ Kirk Kerkorian School of Medicine UNLV, Las Vegas, United States, ² Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States
P 103	ParkinsonGoesDTx – a novel gait monitor concept triggers treatment decisions in
	Parkinson's disease T. Gladow ^{1,2} , <u>S. Stallforth^{2,1}</u> , J. Stiefel ¹ , J. Jukic ² , B. Eskofier ³ , J. Winkler ² , J. Klucken ^{1,2,4,5,6} ¹ Medical Valley Digital Health Application Center, Bamberg, Germany, ² University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Molecular Neurology, Erlangen, Germany, ³ Frie- drich-Alexander-Universität Erlangen-Nürnberg (FAU), Machine Learning and Data Analytics Lab, Erlangen, Germany, ⁴ University of Luxembourg, Digital Medicine Department (LCSB), Luxembourg, Luxembourg, ⁵ Lux- embourg Institute of Health (LIH), Luxembourg, Luxembourg, ⁶ Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg
P 104	Impact of injection guidance techniques on the efficacy and safety of incobo-
	W. Jost ¹ , F. Pagan ² , O. Michel ³ , C. Oehlwein ⁴ , J. Slawek ⁵ , A. Bogucki ⁶ , S. Ochudlo ⁷ , M. Banach ⁸ , B. Flatau-Baqué ⁹ , J. Csikos ⁹ , A. Blitzer ¹⁰ ¹ Parkinson-Klinik, Ortenau, Wolfach, Germany, ² Georgetown University, Washington D.C., United States, ³ University Hospital Brussels, Brussels, Belgium, ⁴ Neurological Outpatient Clinic for Parkinson Disease and Deep Brain Stimulation, Gera, Germany, ⁵ Medical University of Gdansk, Gdansk, Poland, ⁶ Medical University of Lódź, Łódź, Poland, ⁷ Medical University of Silesia, Katowice, Poland, ⁸ Collegium Medicum, Jagiellonian University, Krakow, Poland, ⁹ Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany, ¹⁰ Icahn School of Medicine at Mount Sinai, New York, United States
P 105	Apomorphine sublingual film for "OFF" episodes in Parkinson's disease:
	long-term safety and efficacy <u>S. Factor</u> ¹ , W.G. Ondo ² , S. Isaacson ³ , I. Zhang ⁴ , B. Navia ⁴ , E. Pappert ⁴ ¹ Emory University, Atlanta, United States, ² Methodist Neurological Institute, Houston, United States, ³ Par- kinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, United States, ⁴ Sunovion Pharmaceuticals Inc., Marlborough, United States
P 106	Apomorphine sublingual film has minimal effect on impulse control disorders in long-term treatment of "OFF" episodes in Parkinson's disease <u>A. Espay</u> ¹ , K. Markopoulou ^{2,3} , I. Zhang ⁴ , B. Navia ⁴ , E. Pappert ⁴

¹University of Cincinnati, Cincinnati, United States, ²NorthShore Neurological Institute, Glenview, United States, ³University of Chicago, Chicago, United States, ⁴Sunovion Pharmaceuticals Inc., Marlborough, United States

P 107	Apomorphine sublingual film does not worsen dyskinesia in the long-termtreatment of OFF" episodes in Parkinson's diseaseK.J. Klos ¹ , J.S. Hui ² , I. Zhang ³ , B. Navia ³ , E. Pappert ³ 'The Movement Disorder Clinic of Oklahoma, Tulsa, United States, ² Keck School of Medicine, University ofSouthern California, Los Angeles, United States, ³ Sunovion Pharmaceuticals Inc., Marlborough, United States
P 108	Antiemetics may not be necessary for titration of apomorphine sublingual film for the treatment of "OFF" episodes in Parkinson's disease <u>R.A. Hauser</u> ¹ , S.A. Factor ² , W.G. Ondo ³ , I. Zhang ⁴ , B. Navia ⁴ , E. Pappert ⁴ ¹ University of South Florida, Tampa, United States, ² Emory University, Atlanta, United States, ³ Houston Methodist Neurological Institute, Houston, United States, ⁴ Sunovion Pharmaceuticals Inc., Marlborough, United States
P 109	Apomorphine sublingual film for "OFF" episodes in Parkinson's disease: analysis of baseline factors <u>A.P. Nicholas</u> ¹ , C. Singer ² , I. Zhang ³ , B. Navia ³ , E. Pappert ³ ¹ University of Alabama at Birmingham, Birmingham, United States, ² University of Miami Health System, Miami, United States, ³ Sunovion Pharmaceuticals Inc., Marlborough, United States
P 110	Population pharmacokinetics model of apomorphine (sublingual film or subcutane- ous injection) in healthy subjects and patients with Parkinson's disease (updated) <u>F. Agbo</u> ¹ , R.L. Crass ² , YY. Chiu ¹ , S. Chapel ² , G. Galluppi ¹ , B. Navia ³ ¹ Sunovion Pharmaceuticals, Inc., Fort Lee, United States, ² Ann Arbor Pharmacometrics Group, Inc., Ann Arbor, United States, ³ Sunovion Pharmaceuticals, Inc., Marlborough, United States
P 111	Comparison of pharmacokinetics of apomorphine (sublingual film or subcutaneous injection) between patients with Parkinson's disease in Europe and North America <u>F. Agbo</u> ¹ , S.J. Brantley ² , J. Hu ² , YY. Chiu ¹ , J. Schwarz ³ , F. Stocchi ⁴ , B. Navia ⁵ ¹ Sunovion Pharmaceuticals, Inc., Fort Lee, United States, ² Nuventra, LLC, Durham, United States, ³ Kliniken Kreis Mühldorf, Oberbayern, Germany, ⁴ University and Institute for Research and Medical Care San Raf- faele, Rome, Italy, ⁵ Sunovion Pharmaceuticals, Inc., Marlborough, United States
P 112 (GPT)	Effect of istradefylline dosage on unified Parkisons' disease rating scale (UPDRS) III-ON scores: results from four randomized clinical trials J. Kulisevsky ¹ , Y. Nakajima ² , N. Kronfeld ³ , S. King ⁴ , A. Mori ⁵ ¹ Sant Pau Hospital, Universitat Autònoma de Barcelona, Ciberned, Barcelona, Spain, ² Kyowa Kirin, Inc., Biometrics, Princeton, United States, ³ Kyowa Kirin, Inc., Medical Affairs, Marlow, United Kingdom, ⁴ Kyowa Kirin, Inc., Medical Affairs, Bedminster, United States, 5Kyowa Kirin Co., Ltd., Medical Affairs, Tokyo, Japan
P 113 (GPT)	SAGE-718 in Parkinson's disease mild cognitive impairment: results from the Phase 2 PARADIGM Study <u>A. Koenig</u> ¹ , J. Johannesen ¹ , E. Freitag ¹ , S. Li ¹ , J. Petrillo ¹ , J. Wald ¹ , K. Paumier ¹ , M. Quirk ¹ , J. Doherty ¹ 'Sage Therapeutics, Inc., Cambridge, United States
P 114	The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study <u>O. Klepitskaya</u> ¹ , A. Vijan ¹ , K. Olson ¹ , T. O'Reilly ² , G. Liang ¹ , G. Loewen ¹ ¹ Neurocrine Biosciences, Inc., San Diego, United States, ² Celerion, Inc., Tempe, United States
P 116 (GPT)	A novel treatment for Apraxia of Eyelid Opening using a pulsating headband: a single-centre pilot study <u>S. Arjun</u> ¹ , H. Singh ¹ , N. Sawal ² , M. Matta ¹ ¹ Government Medical College and Hospital, Chandigarh, India, ² Fortis Mohali, Neurology, Mohali, India
P 117 (GPT)	Bezoar And Catheter Knotting As Rare Complications Of Levodopa Carbidopa Intestinal Gel Therapy <u>T. Saltoğlu</u> ¹ , Y. Sücüllü Karadağ ¹ ¹ Ankara City Hospital, Ankara, Turkey

P 120	Long-term safety of continuous levodopa/carbidopa infusion with ND0612: results from the ongoing BeyoND study <u>W. Poewe</u> ¹ , F. Stocchi ² , S. Sopromadze ³ , L. Adar ³ , N. Sasson ³ , T. Yardeni ³ , N. Giladi ⁴ ¹ Medical University Innsbruck, Department of Neurology, Innsbruck, Austria, ² University and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy, ³ NeuroDerm, Rehovot, Israel, ⁴ Neurological Institute, Tel Aviv Medical Center, Sackler School of Medicine, Sagol School of Neurosciences, Tel Aviv, Israel
P 121	Population pharmacokinetics of levodopa and carbidopa following subcutaneous infusion <u>T. Birnberg</u> ¹ , L. Adar ¹ , G. Smania ² , M. Bjornsson ² , N. Jonsson ² , R. Case ² , M.O. Karlsson ³ ¹ NeuroDerm, Rehovot, Israel, ² Pharmetheus, Uppsala, Sweden, ³ Uppsala University, Uppsala, Sweden
P 122	 Nicotinamide riboside alleviates Parkinson's disease symptoms but downregulates dopamine metabolism <u>G. Turconi</u>¹, F. Alam², T. SenGupta³, S. Pirnes-Karhu², S. Olfat², M. Schmidt⁴, K. Mätlik², A. Montaño-Rodriguez², V. Heiskanen², P. Piepponen², C. Brenner⁵, C. Holmberg², H. Nilsen³, JO. Andressoo^{2,6}, E. Pirinen² ¹University of Helsinki, Pharmacology & HiLIFE, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, 3University of Oslo, Oslo, Norway, ⁴University of Iowa, Iowa, United States, ⁵City of Hope National Medical Center, Duarte, United States, 6Karolinska Institute, Stockholm, Sweden
P 123	Mode of action of the neurotrophic factor CDNF as a potential drug for Parkinson's disease <u>V. Kovaleva</u> ¹ , O. Shpironok ¹ , L. Ivanova ² , LY. Yu ¹ , M. Karelson ² , M. Saarma ¹ ¹ University of Helsinki, Institute of Biotechnology, HiLIFE, Helsinki, Finland, ² University of Tartu, Institute of Chemistry, Tartu, Estonia
P 124 (GPT)	Adverse effects of levodopa/carbidopa intrajejunal gel treatment: a single center long-term prospective study <u>M. Premzl</u> ¹ , T. Rus1, M. Trošt ^{1,2} ¹ UMC Ljubljana, Department of Neurology, Ljubljana, Slovenia, ² University of Ljubljana, Medical Faculty, Ljubljana, Slovenia
P 125	GT-02287, a brain-penetrant structurally targeted allosteric regulator for gluco- cerebrosidase show evidence of pharmacological efficacy in models of Parkinson's disease <u>B. Guzman¹</u> , N. Perez ² , A.M. Garcia ² , E. Cubero ² , X. Barril ² , M. Bellotto ¹ , S. Morales ² , A. Ruano ² , A. Delgado ² , C. Poletto ³ , G. Forloni ³ , R. Maj ¹ ¹ Gain Therapeutics, Lugano, Switzerland, ² Gain Therapeutics, Barcelona, Spain, ³ Istituto di Ricerche Farma- cologiche IRCCS, Neuroscience, Milan, Italy
P 126	Switching and combining device-aided therapies in advanced Parkinson's disease: a double centre retrospective study <u>S. Delalić</u> ¹ , D. Georgiev ^{2,3} , N. Zupančič Križnar ² , A. Socher ⁴ , T. Gurevich ⁴ , M. Trošt ^{2,5} ¹ General Hospital of Isola, Department of Neurology, Isola, Slovenia, ² University Medical Centre Ljubljana, Department of Neurology, Ljubljana, Slovenia, ³ University of Ljubljana, Faculty of Computer and Informa- tion Sciences, Ljubljana, Slovenia, ⁴ Tel Aviv Sourasky Medical Centre, Movement Disorders Unit, Tel Aviv, Israel, ⁵ University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
P 127 (GPT)	Setting the TEMPO: A phase 3 program to investigate tavapadon, a selective D1/D5 partial agonist, for Parkinson's disease <u>H.F. Fernandez</u> ¹ , S.P. Pfister ² , M. Leoni ² , M. Berry ² , A. Gangadharan ² , S. Duvvuri ² , J. Parker ² , S. Wang ² , R.B. Briscoe ² , R. Sanchez ² 'Cleveland Clinic, Cleveland, United States, ² Cerevel Therapeutics, Cambridge, United Kingdom
P 128 (GPT)	Advanced therapies for Parkinson's disease (PD) in the age of telehealth <u>Z. Mari</u> ¹ ¹ Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, United States

P 129	Fears and certainties of chilean neurologists in the therapeutic approach to parkinson's disease <u>P. Salles</u> ¹ , M. Teran-Jimenez ^{1,2} , BH. Palma ¹ , M. Retamal ¹ , P. Chana-Cuevas ^{1,3} ¹ Centro de Trastornos del Movimiento CETRAM, Santiago, Chile, ² Felix Bulnes Hospital, Movement Disor- ders Section, Santiago, Chile, ³ University of Santiago de Chile, Faculty of Medical Sciences, Santiago, Chi
P 129-I	 Pimavanserin is not associated with elevated risk of mortality in patients with Parkinson's disease psychosis S. Isaacson¹, F. Pagan², D.Truong³, V.Abler⁴, R. Pahwa⁵ ¹Parkinson's Disease and Movement Disorders of Boca Raton, Boca Raton, FL, USA; ²Department of Neuro ogy, Georgetown University Medical Center, Washington, DC, USA; ³The Parkinson and Movement Disorder Institute, Fountain Valley, CA and Department of Psychiatry and Neuroscience, University of California Riverside, Riverside, CA, USA; ⁴Acadia Pharmaceuticals Inc., San Diego, CA, USA; ⁵Department of Neurolo- gy, University of Kansas Medical Center, Kansas City, KS, USA
Topic: Parkins	on Disease: Other topics
P 130 (GPT)	If not insulin resistance so what? Comparison fasting glycaemia in idiopathic Parkinson's disease and atypical parkinsonism <u>T. Chmiela</u> ¹ , J. Węgrzynek ² , A. Kasprzyk ² , D. Waksmundzki ² , D. Wilczek ² , A. Gorzkows- ka ³
	ice, Poland, ² Faculty of Medical Sciences in Katowice, Medical University of Silesia, Department of Neurology, Katow- ice, Poland, ² Faculty of Medical Sciences in Katowice, Medical University of Silesia, Students' Scientific Association, Department of Neurorehabilitation, Katowice, Poland, ³ Faculty of Medical Sciences in Katow ice, Medical University of Silesia, Department of Neurorehabilitation, Katowice, Poland
P 131 (GPT)	Burning mouth syndrome to oral cenesthopathy: a spectrum of neuropsychiatric and sensory complications in neurodegenerative parkinsonism J.R.T. Yu ¹ , X.X. Yu ¹ , R. Rajaram ² , H. Fernandez ¹ , J. Siddiqui ¹ ¹ Cleveland Clinic, Neurological Institute, Cleveland, United States, ² Cleveland Clinic, Department of Psych atry, Cleveland, United States
P 132	 Possible link between cognition and motor reserve in patients with Parkinson's disease <u>S.J. Chung</u>^{1,2}, Y.J. Kim³, Y.J. Kim², M. Yun⁴, P.H. Lee¹, Y. Jeong⁵, Y.H. Sohn¹ ¹Yonsei University College of Medicine, Department of Neurology, Seoul, Korea, Republic of, ²Yongin Severance Hospital, Department of Neurology, Yongin-si, Korea, Republic of, ³Korea Advanced Institute of Science and Technology, Program of Brain and Cognitive Engineering, Daejeon, Korea, Republic of, ⁴Yonsei University College of Medicine, Department of Nuclear Medicine, Seoul, Korea, Republic of, ⁵Korea Advanced Institute of Science and Technology, Department of Bio and Brain Engineering, Daejeon, Korea, Republic of
P 133	Sleep problems in Parkinson's disease: PD patients' survey on common issues and treatments expectations N. Singer ¹ , N. Ratcliffe ² , R. Fisher ¹ , K. Fletcher ² , E. Eyal ¹ , <u>E. Berkovich¹</u> 'Clexio Biosciences LTD, Petach Tikva, Israel, ² Parkinson's UK, London, United Kingdom
P 134	Optimization of recruitment for movement disorders clinical trials in a pandemic: a single center experience <u>O. Phillips</u> ¹ , J. Kosco ¹ , M. Serrano ¹ , H. Fernandez ¹ ¹ Cleveland Clinic, Center for Neurological Restoration, Cleveland, United States
P 135	Obstructive Sleep Apnea (OSA) detection system based on Fast Fourier Transform (FFT) algorithm on electrocardiogram <u>R. Fajar¹</u> , N.I. Kurniastuti ¹ , T.H. Wulandari ¹ ¹ Yogyakarta State University, Computational Biology and Medicine Laboratory, Sleman, Indonesia
P 136	Correlation analyses of serum cytokine in Parkinson's disease and

Parkinsonism-plus syndrome <u>X. Chen</u>¹, H. Shang¹, J. Liu¹ ¹Sichuan University, Chengdu, China

Model of virtual communication of the Reference center for invasive methods of treatment of Parkinson's disease during the COVID-19 pandemic <u>V. Komen</u> ¹ , E. Papic ^{1,2} , G. Rozmaric ¹ , V. Vuletic ^{1,2} 'Clinical Hospital Center Rijeka, Clinic of Neurology, Rijeka, Croatia, ² Faculty of Medicine, University of
Rijeka, Department of Neurology, Rijeka, Croatia
Assessment of bilirubin levels in Parkinson's disease <u>E. Kobak Tur</u> ¹ , B.C. Ari ² ¹ Healthy Science University Istenbul Fatib Sultan Mehmet Training and Research Heapital Neurology
Istanbul, Turkey, ² Bahcesehir University School of Medicine, Neurology, Istanbul, Turkey
The conjugacy of migraine and parkinsonism, from theory to practice N. Panoeva ¹ , M. Gulova ¹ , <u>M. Sanoeva²</u> ¹ Bukhara State Medicine Institute, Neurology, Bukhara, Uzbekistan, ² Tashkent Medical Academy, Neurology
and Medicine Psychology, Tashkent, Uzbekistan
Hippocampal and amygdala atrophy rates correlate with the severity of sleep apnoea in Parkinson's disease
<u>K. Burdova</u> ', P. Filip', K. Sonka', P. Dusek', J. Nepozitek', P. Stofanikova', S. Dostalova', P. Peřinová ¹ , R. Jech ¹
and Centre of Clinical Neuroscience, Prague, Czech Republic
A Croatian tertiary center experience on the impact of the COVID-19 pandemic on Parkinson's disease: a cross-sectional telephone study <i>M. Hero</i> ^{1,2} , <i>G. Rožmarić</i> ³ , <i>V. Rački</i> ^{1,2} , <i>V. Vuletić</i> ^{1,2}
¹ Clinic of Neurology, Clinical Hospital Center Rijeka, Rijeka, Croatia, ² Faculty of Medicine, University of Rijeka, Department of Neurology, Rijeka, Croatia, ³ Faculty of Medicine of the University of Rijeka, Rijeka, Croatia
Impact of telemedicine among Parkinson's disease patients during COVID-19
<u>R. Ojha</u> ¹ , R. Karn ¹ , B.P. Gajurel ¹ , R. Rajbhandari ¹ , N. Gautam ¹ , A. Shrestha ¹ , J.K. Yadav ² , P. Joshi ² , G. Nepal ²
¹ Tribhuvan University Institute of Medicine, Maharajgunj Medical Campus, Department of Neurology, Kathmandu, Nepal, ² Tribhuvan University Institute of Medicine, Maharajgunj Medical Campus, Department of Medicine, Kathmandu, Nepal
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated
with amantadine <u>J. Sławek</u> ¹ , F. Przytuła ² , J. Kasprzak ² , J. Dulski ² ¹ Medical University of Gdańsk, Department of Neurological-Psychiatric Nursing, Gdańsk, Poland, ² St. Adal-
bert Hospital, Neurology&Stroke Dpt., Gdańsk, Poland
Comparison of patient preferences for Parkinson's disease treatments and
M. Serbin¹, C. Mansfield², C. Leach², C. Yonan¹, M. Sheehan³, A. Donnelly⁴, O. Klepitskaya¹
¹ Neurocrine Biosciences, San Diego, United States, ² RTI Health Solutions, Research Triangle Park, United States, ³ Ashurst, Washington, United States, ⁴ Northwestern University, Evanston, United States
Malnutrition status and cognitive functions correlation in patients with Parkinson's disease and atypical parkinsonisms: a preliminary study V. Ferri ¹ , M. Barichella ² , <u>S. Bonvegna^{1,2}</u> , E. Cereda ³ , L. Zocchi ⁴ , C. Castelli ² , C. Pusani ² , C. Bolliri ¹ , S. Caronni ¹ , M.C. Macchione ¹ , G. Legnani ² , D. Calandrella ¹ , F. Garri ¹ , G. Sacilotto ² , M. Zini ² , F. Del Sorbo ² , V. Cereda ¹ , B. Pozzi ¹ , G. Pezzoli ¹ ¹ Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy, ² ASST Pini-CTO, Milan, Italy, ³ IRCCS Policlinico San Matteo, Pavia, Italy, ⁴ Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Facoltà di Me- dicina e Chirurgia, Università degli Studi di Milano, Milano, Italy

P 146	Interaction lead neurotoxicity and Parkinson's disease In vivo study <u>N. Mostefa</u> ¹ , N. Djebli ¹ ¹ Pharmacognosy & Api Phytotherapy Laboratory, Mostaganem University, Mostaganem, Algeria
P 147 (GPT)	Violation of motor and non-motor functions in patients with COVID-19 with oral pathology M. Giyazova ¹ , M. Sanoeva ² ¹ Bukhara State Medicine Institute, Physiology, Bukhara, Uzbekistan, ² Tashkent Medical Academy, Neurolo- gy and Medicine Psychology, Tashkent, Uzbekistan
P 148	The role of vascular factors in Parkinson's disease and vascular parkinsonism <u>SJ. Khamdamov</u> ¹ , D. Akramova ¹ , S. Kuranbaeva ¹ , U. Shamsieva ¹ , Y. Musaeva ¹ , S. Kalandarova ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan
P 149	Analysis of MRT results in Parkinson's disease, vascular Parkinsonism and chronic ischemia of the brain <u>A. Umirov</u> ¹ , S. Kuranbayeva ¹ ¹ Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan
P 150	Biomarkers for Parkinson's Disease with Reflex Tears Stratified by Disease Duration <u>M. Lew</u> ¹ , S. Janga ² , Y. Ju ² , D. Feigenbaum ¹ , A. Besharat ¹ , D. Freire ¹ , D. Gerke ³ , M. Edman ² , W. Mack ⁴ , C. Okamoto ⁴ , S. Hamm-Alvarez ² ¹ Keck/USC School of Medicine, Neurology, Los Angeles, United States, ² Keck/USC School of Medicine, Ophthal- mology, Los Angeles, United States, ³ Keck/USC School of Medicine, Translational Genomics, Los Angeles, Uni- ted States, ⁴ Keck/USC School of Medicine, Population and Public Health Sciences, Los Angeles, United States
Topic: Other Parl	kinsonian Disorders
P 152	L-Dopa responsiveness in Perry syndrome (parkinsonism, depression, weight loss, hypoventilation)

nypovenulation)
<u>J. Dulski^{1,2}, C. Cerquera-Cleves^{3,4}, L. Milanowski^{5,6,7}, J. Kwiatek-Majkusiak⁷,</u>
D. Koziorowski ⁷ , O.A. Ross ⁶ , J. Pentela-Nowicka ⁸ , J. Slawek ^{1,2} , Z.K. Wszolek ⁵
¹ Medical University of Gdansk, Division of Neurological and Psychiatric Nursing, Faculty of Health Scienc-
es, Gdansk, Poland, ² St. Adalbert Hospital, Copernicus PL, Neurology Department, Gdansk, Poland, ³ Pontif-
icia Universidad Javeriana, San Ignacio Hospital, Neurology Unit, Bogotá, Colombia, ⁴Clínica Universitaria
Colombia, Movement Disorders Clinic, Bogotá, Colombia, ⁵Mayo Clinic, Department of Neurology, Jack-
sonville, United States, ⁶ Mayo Clinic, Department of Neuroscience, Jacksonville, United States, ⁷ Medical
University of Warsaw, Department of Neurology, Faculty of Health Science, Warsaw, Poland, ⁸ Medical
University of Lodz, Departement of Neurology, Lodz, Poland

P 153 (GPT) A novel C19ORF12 mutation in a MPAN family with the treatment of deferiprone S. Chen¹

¹Sichuan University, West Hospital, Chengdu, China

P 154 Autonomic nervous system dysfunction in cases of neurodegeneration associated with mutations in C19orf12 <u>M. Skowronska</u>¹, J. Bembenek², M. Rydzewski¹, T. Litwin¹, A. Antos¹, A. Czlonkowska¹, I. Kurkowska Jastrzebska¹

> ¹Institute of Psychiatry and Neurology, 2nd Department of Neurology, Warsaw, Poland, ²Institute of Psychiatry and Neurology, Department of Clinical Neurophysiology, Warsaw, Poland

P 155	Progressive Supranuclear Palsy Parkinsonism-Predominant (PSP-P) – a problematic entity in the examination of parkinsonisms <u>P. Alster</u> ¹ , M. Nieciecki ² , B. Migda ³ , M. Kutyłowski ⁴ , N. Madetko ⁵ , K. Duszyńska-Wąs ⁶ , <u>D. Koziorowski¹, L. Królicki⁷, A. Friedman¹</u> ¹ Medical University of Warsaw, Neurology, Warsawa, Poland, *Children's Memorial Health Institute, Nucle- ar Medicine, Warszawa, Poland, ³ Medical University of Warsaw, Diagnostic Ultrasound Lab, Department of Pediatric Radiology, Warszawa, Poland, ⁴ Mazovian Brodnowski Hospital, Department of Radiology, Warsza- wa, Poland, ⁵ Medical University of Warsaw, Neurology, Warszawa, Poland, ⁶ Mazovian Brodnowski Hospital, Neurology, Warszawa, Poland, ⁷ Medical University of Warsaw, Nuclear Medicine, Warszawa, Poland
P 156	Health-related quality of life in multiple system atrophy using EQ-5D-5L: a large cross-sectional study in China <u>Y. Xiao</u> ¹ , L. Zhang ¹ , Q. Wei ¹ , R. Ou ¹ , Y. Hou ¹ , K. Liu ¹ , J. Lin ¹ , T. Yang ¹ , H. Shang ¹ 'Sichuan University, Chengdu, China
P 157 (GPT)	Lipid profile as a differentiating factor in PSP-Richardson-Steele syndrome and Corticobasal syndrome <u>N. Madetko</u> ¹ , P. Alster ¹ , D. Koziorowski ¹ , A. Friedman ¹ ¹ Medical University of Warsaw, Department of Neurology, Warsaw, Poland
P 160 (GPT)	Prediction of disability in multiple system atrophybased on machine learning algorithm <u>L. Zhang</u> ¹ , Y. Hou ¹ , X. Gu ¹ , B. Cao ¹ , Q. Wei ¹ , R. Ou ¹ , K. Liu ¹ , J. Lin ¹ , T. Yang ¹ , Y. Xiao ¹ , Y. Chen ¹ , B. Zhao ¹ , H. Shang ¹ ¹ West China Hospital Sichuan University, Neurology, Chengdu, China
P 161	Polysomnographic study: characteristics of sleep disturbances in patients with Parkinson's disease <u>S. Kurbonov</u> ¹ , G. Rakhimbaeva ¹ , G. Goyibova ² ¹ Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan, ² Tashkent Pediatric Medical Institute, Department of Neurology, Tashkent, Uzbekistan
P 162	Clinical and neurophysiological features of sensory dysfunction in Parkinson's disease patients in Uzbekistan <u>S. Kurbonov</u> ¹ , G. Rakhimbaeva ¹ , G. Goyibova ² ¹ Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan, ² Tashkent Pediatric Medical Institute, Department of Neurology, Tashkent, Uzbekistan
P 163	Clinical presentation and diagnosis of a rare brain disease – progressive supranuclear palsy <u>A. Angelova</u> ¹ , G. Novotni ² , F. Stojkovska ³ ¹ University Clinic for Neurology, Skopje, North Macedonia, The Republic of, ² University Clinic for Neurology, Ss Cyril and Methodius University-Faculty of Medicine, Neuroimmunology, Skopje, North Macedonia, The Republic of, ³ University Clinic for Neurology, Ss Cyril and Methodius University-Faculty of Medicine, Neuro- muscular Disorders, Skopje, North Macedonia, The Republic of
P 164	Progressive supranuclear palsy <u>I. Skenderoska</u> ¹ ¹ Center for Orthopaedic and Traumatolgy St. Erasmo, Neurology, Ohrid, North Macedonia, The Republic of
P 165	 Phenotypic spectrum of progressive supranuclear palsy: clinical study and APOE effect <u>A. Gharbi</u>¹, S. Mrabet^{1,2}, Y. Abida¹, I. Sghaier¹, A. Souissi¹, A. Gargouri^{1,2}, A. Nasri^{1,2}, I. Kacem^{1,2}, R. Gouider^{1,2} ¹Razi University Hospital, Department of Neurology, LR18SP03, Manouba, Tunisia, ²Faculty of Medicine of Tunis University of Tunis El Manar, Tunis, Tunisia
P 166	Orthostatic hypotension – insidious onset of MCA-C <u>F. Stojkovska</u> ¹ , Z. Chanakovski ² ¹ University Clinic of Neurology, neurology, Skopje, North Macedonia, The Republic of, ² Military Medical Center, Neurology, Skopje, North Macedonia, The Republic of

P 167 (GPT)	Can restless legs syndrome be a predictor of parkinsonism in patients with migraine comorbid with hypertension? <u>M. Gulova</u> ¹ , M. Sanoeva ² , N. Panoeva ¹ ¹ Bukhara State Medical Institute, Neurology, Bukhara, Uzbekistan, ² Tashkent Medical Academy, Neurology and Medicine Psychology, Tashkent, Uzbekistan
P 168	Features of the specific clinical manifestations of vascular disorders in Parkinson's disease and vascular parkinsonism <u>D. Akramova</u> ¹ , G. Rakhimbaeva ¹ , T. Bobomuratov ¹ , U. Shamsieva ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan
P 169	Development of osteomyelitis after COVID 19 in patients with vascular parkinsonism <u>D. Bobamuratova^{1,1}, T. Bobomuratov¹, D. Akramova¹</u> ¹ Tashkent Medical Academy, Tashkent, Uzbekistan
P 170	Cavernous sinus thrombosis in patients after coronavirus disease patients with vascular parkinsonism in Uzbekistan <u>D. Bobamuratova</u> ¹ , S. Boymuradov ¹ , T. Bobomuratov ¹ , D. Akramova ¹ ¹ Tashkent Medical Academy, Tashkent, Uzbekistan
Topic: Dystonia	
P 171 (GPT)	Effects of botulinum toxin type A in Meige's syndrome <u>A. Duarte</u> ¹ , H.A. Ghizoni Teive ¹ ¹ Universidade Federal do Paraná, Curitiba, Brazil
P 172	A multimodal meta-analysis of structural and functional brain changes in idiopathic blepharospasm <u>M. Zhang</u> ¹ , X. Huang ¹ , H. Shang ¹ , J. Yang ¹ ¹ West China Hospital of Sichuan University, Neurology, Chengdu, China
P 173	IncobotulinumtoxinA injections at intervals <10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard intervals <u>C. Comella</u> ¹ , R. Hauser ² , S. Isaacson ³ , D. Truong ⁴ , O. Oguh ⁵ , J. Hui ⁶ , E. Molho ⁷ , M. Brodsky ⁸ , E. Furr-Stimming ⁹ , G. Comes ¹⁰ , M. Hast ¹¹ , D. Charles ¹² 'Rush University Medical Center, Chicago, United States, ² University of South Florida Health Byrd Institute, Tampa, United States, ³ Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, United States, ⁴ UC Riverside, Riverside, United States, ⁵ Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States, ⁶ University of Southern California, Los Angeles, United States, ⁷ Albany Medical Center Neurosciences Institute, Albany, United States, ⁸ Oregon Health & Science University, Portland, United States, ⁹ The University of Texas Health Science Center at Houston, Houston, United States, ¹⁰ Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany, ¹¹ Merz Pharmaceuticals, LLC, Raleigh, United States, ¹² Vanderbilt University Medical Center, Nashville, United States
P 174	Cervical dystonia with cerebellar ataxia in KCNA1 mutation: a phenotypic expansion <u>R. Mahale</u> ¹ , S Jayanth ¹ , D. Dutta ¹ , H. Padmanabha ¹ , P. Mailankody ¹ ¹ NIMHANS, Bangalore, India
P 175 (GPT)	Biopsychosocial aspect of patients with X-Linked Dystonia-Parkinsonism: Its implications on quality of life <u>A. Alcachupas</u> ^{1,2} , K. Bellosillo ¹ , W.R. Catolico ¹ , M.C. Davis ¹ , A. Diaz ¹ , Y.K. Doyongan ¹ , R. Eduarte ¹ , E. Gersava ¹ , M.B. Intrepido ¹ , M.G.K. Laluma ¹ , C.C. Lavalle ¹ , J.J. Millan ¹ ¹ West Visayas State University, College of Medicine, Iloilo City, Philippines, ² Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
P 176 (GPT)	Depression impact on subjective and objective severity of cervical and segmental dystonia <u>V. Meļņikova</u> ¹ , R. Valante ¹ , S. Valtiņa-Briģe ¹ 'Pauls Stradiņš Clinical Univerity Hospital, Department of Neurology, Rīga, Latvia

P 177 (GPT)	Clinical aspects of patients with blepharospasm in Latvia: one center study <u>M. Kalniņa^{1,2}, R. Valante¹, K. Lazdovska¹</u> ¹ Pauls Stradiņš Clinical University Hospital, Department of Neurology, Riga, Latvia, ² Rīga Stradiņš Universi-
	ty, Faculty of Residency, Riga, Latvia
P 178 (GPT)	Data of P. Stradins Clinical University Hospital Dystonia Register: time from symptoms to diagnosis and treatment of blepharospasm <u>M. Kalniņa^{1,2}</u> , R. Valante ¹ , K. Lazdovska ¹ ¹ Pauls Stradiņš Clinical University Hospital, Department of Neurology, Riga, Latvia, ² Rīga Stradiņš Universi- tv. Faculty of Residency. Riga, Latvia
P 179 (GPT)	Comparing the features of cervical dystonia subtypes: a retrospective study in Pakistan <u>A. Fatima¹</u> ¹ Fatima Jinnah Medical University/Sir Gangaram Hospital, Neurology, Labore, Pakistan
P 180	Non-motor symptoms in cervical dystonia <u>E. Kobak Tur</u> ¹ , K.I. Carus ¹ , E. Gözke ¹ ¹ Healthy Science University Istanbul Fatih Sultan Mehmet Training and Research Hospital. Istanbul. Turkey
P 181	Dystonia 23: first report of a Colombian case <u>D. García-Orjuela</u> ¹ , X. García ² ¹ Pontificia Universidad Javeriana, Neuroscience, Bogotá, Colombia, ² C.I.F.E.L., Movement Disorders, Bogotá, Colombia
P 182	Clinical characteristic of hemifacial spasm patients in Latvian population <u>A. Dubra^{1,2}</u> ¹ Riga Stradiņš University, Neurology, Riga, Latvia, ² Pauls Stradins Clinical University Hospital, Neurology, Riga, Latvia
P 183	Generalized dystonia of early onset associated with a homozygous loss-of-function variant in the AOPEP gene <u>C. Fevga</u> ¹ , F. Ferraro ¹ , G.J. Breedveld ¹ , C. Savant Sankhla ² , V. Bonifati ¹ ¹ Erasmus MC, University Medical Center Rotterdam, Clinical Genetics, Rotterdam, Netherlands, ² P D Hindu- ja National Hospital, Neurology, Mahim, Mumbai, Maharashtra, India
P 184	Health-related quality of life in cervical dystoniausing EQ-5D-5L: a large cross-sectional study in China <u>J. Lin</u> ¹ , Y. Liang ¹ , R. Ou ¹ , Q. Wei ¹ , Y. Hou ¹ , L. Zhang ¹ , C. Li ¹ , K. Liu ¹ , Z. Jiang ¹ , T. Yang ¹ , J. Yang ¹ , M. Zhang ¹ , S. Kang ¹ , Y. Xiao ¹ , Q. Jiang ¹ , X. Gu ¹ , J. Yang ¹ , W. Song ¹ , X. Chen ¹ , B. Zhao ¹ , Y. Wu ¹ , H. Shang ¹ ¹ West China Hospital, Sichuan University, Chengdu, China
P 185 (GPT)	Mutation screening and burden analysis of IMPDH2 in dystonia in a Chinese population <u>J. Lin</u> ¹ , C. Li ¹ , X. Gu ¹ , Y. Cui ¹ , Y. Hou ¹ , L. Zhang ¹ , R. Ou ¹ , Q. Wei ¹ , B. Cao ¹ , K. Liu ¹ , Z. Jiang ¹ , T. Yang ¹ , J. Yang ¹ , M. Zhang ¹ , S. Kang ¹ , Y. Xiao ¹ , Q. Jiang ¹ , W. Song ¹ , B. Zhao ¹ , J. Yang ¹ , X. Chen ¹ , Y. Wu ¹ , H. Shang ¹
P 186	Whole exome sequencing of familial, combined or complex dystonia <u>E. Kafantari</u> ¹ , A. Puschmann ¹ ¹ Lund University, Skåne University Hospital, Neurology, Lund, Sweden

P 187 (GPT)	Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia <u>M. Krygier</u> ¹ , M. Zawadzka ¹ , K. Rutkowska ² , J. Sławek ^{3,4} , M. Vernet Machado Bressan Wilke ⁵ , E.W. Klee ⁵ , L.A. Schimmenti ⁶ , R. Płoski ² , M. Mazurkiewicz-Bełdzińska ¹ ¹ Medical University of Gdansk, Department of Developmental Neurology, Gdansk, Poland, ² Medical Univer- sity of Warsaw, Department of Medical Genetics, Warsaw, Poland, ³ Medical University of Gdansk, Depart- ment of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Gdansk, Poland, ⁴ St Adalbert Hospital, Neurology Department, Gdańsk, Poland, ⁵ Mayo Clinic, Center for Individualized Medicine, Roch- ester, United States, ⁶ Mayo Clinic, Department of Clinical Genomics, Rochester, United States
P 188	Structural Cerebellar Lobules Correlates of Dystonic Head Rotation in Idiopathic Cervical Dystonia <u>m. Qiu</u> ¹ , I. Feng ¹ , I. Jin ² ¹ Shanghai Tongji University, Neurotoxin Research center of Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Neurological Department of Tongji Hospital, School of Mediceine, Tongji University, Shanghai, China, Shanghai, China, ² Shanghai Tongji University, Department of Neurology and Neurological Rehabilitation, Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai 201619, China, Shanghai, China
Topic: Chorea, A	thetosis, Ballism, Tics
P 189 (GPT)	Functional chorea diagnosed in a patient with schizophrenia treated with paliperidone: extrapyramidal side effect or functional? <u>F. Erdogan Kucukdagli</u> ¹ , T. Saltoglu ¹ , Y. Sucullu Karadag ¹ ¹ Ankara City Hospital, Department of Neurology, Ankara, Turkey
P 190	Heat-induced tic reduction in Gilles de la Tourette syndrome <u>A. Durbin</u> ¹ , J. Brasic ¹ ¹ Johns Hopkins University, Baltimore, United States
P 191 (GPT)	Fingolimod-responsive complex hyperkinetic movement disorder in neuromyelitis optica spectrum disorder <u><i>R.E. Cortes</i>¹, J.A. Vatanagul¹, G. Saranza² ¹Perpetual Succour Hospital of Cebu, Inc., Internal Medicine, Cebu City, Philippines, ²Chong Hua Hospital, Neurology, Cebu City, Philippines</u>
P 192 (GPT)	Characteristics of tics in follow-up study of community-based high risk cohort of 2511 children <u>N. Szejko^{1,1}</u> , P. Macul Ferreira de Barros ² , M. Panczyk ¹ , P.M. Pan ² , P. Gomez de Alvaren- ga ² , M. Hoextra ² , K. Timpano ³ , J. Leckman ⁴ , E. Miguel ² ¹ Medical University of Warsaw, Warsaw, Poland, ² Institute of Psychiatry, Sao Paulo, Brazil, ³ University of Miami, Miami, United States, ⁴ Yale University, New Haven, United States
P 193	Klazomania in Gilles de la Tourette syndrome <u>J. Kaczyńska</u> ¹, P. Janik¹ ¹Medical University of Warsaw, Department of Neurology, Warsaw, Poland
P 194	EEG findings in Gilles de la Tourette syndrome <u>C. Rajczewska-Oleszkiewicz</u> ¹ , J. Kaczyńska ¹ , P. Janik ¹ ¹ Medical University of Warsaw, Department of Neurology, Warszawa, Poland
P 195 (GPT)	Moving toes in 28-year-old woman: a video case report <u>C. Rajczewska-Oleszkiewicz</u> ¹ , P. Janik ¹ 1Medical University of Warsaw, Department of Neurology, Warszawa, Poland
P 196	Correlation-gender features in patients with Huntington's disease in Uzbekistan <u>A. Umarov</u> ¹ , G. Rahimbaeva ¹ , G. Goyibova ² ¹ Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan, ² Tashkent Pediatric Medical Institute, Department of Neurology, Tashkent, Uzbekistan

P 197 (GPT)	Common pitfalls in recognition of an age old malady: edentulous stereotypy <u>S. Desai¹</u> , D. Desai ² ¹ Shree Krishna Hospital and Pramukhswami Medical College Bhaikaka University, Neurology, Anand, India, ² Shree Krishna Hospital and Pramukhswami Medical College Bhaikaka University, Medicine, Anand, India
P 198	Early onset hemichorea-parkinsonism with POLG mutation without external ophthalmoplegia responsive to pallidal DBS F. Garrì ¹ , D. Calandrella ¹ , <u>S. Bonvegna^{1,2}</u> , F. Del Sorbo ² , G. Sacilotto ² , M. Zini ² , C. Bolliri ¹ , V. Cereda ¹ , V. Ferri ¹ , M. Barichella ^{1,2} , G. Pezzoli ¹ ¹ Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy, ² Parkinson Institute, ASST G. Pini-CTO, Milan, Italy
P 200	Study of the difficulties of late diagnostics in patients with Huntington's disease in Uzbekistan <u>A. Ismatov</u> ¹ , D. Tolibov ¹ , A. Umarov ¹ ¹ Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan
P 201	"Levine-Critchley syndrome" – obsolete A. Danek ¹ , N. Krstić ² , M.T. Hayes ³ , R.C. Green ³ , C. Westhoff ⁴ , S. Vege ⁴ , <u>R.H. Walker</u> ⁵ ¹ Ludwig-Maximilians-Universität, Munich, Germany, ² USF Health-Morsani College of Medicine, Tampa, United States, ³ Harvard Medical School, Boston, United States, ⁴ New York Blood Center, New York, United States, ⁵ Mount Sinai School of Medicine, New York, United States
Topic: Ataxias, H	ereditary Spastic Paraparesis
P 202	Late-onset cerebellar ataxia: case report of a new CNV on TTBK2 gene as possible cause of SCA-11 <u>I. Rodriguez</u> ¹ , A. Bochm ² , E. Davila ² , D. Martinez ¹ ¹ Instituto Tecnologico y de Estudios Superiores de Monterrey, Neurología, Monterrey, Mexico, ² Instituto Tecnologico y de Estudios Superiores de Monterrey, Escuela de Medicina, Monterrey, Mexico
P 203	Spastic ataxic phenotype of Fatty acid 2-hydroxylase associated neuro- degeneration: a case series from India <u>V.V Holla</u> ¹ , N. Sriram ¹ , R. Kumari ² , N. Kamble ¹ , R. Yadav ¹ , B. Muthusamy ² , P.K. Pal ¹ ¹ National Institute of Mental Health and Neurosciences, Neurology, Bengaluru, India, ² Institute of Bioinfor- matics, Bengaluru, India
P 204	A Swedish SCA34 family with late onset ataxia, cerebellar atrophy and ocular movement abnormalities with a novel mutation in ELOVL4 <u>S. Dobloug</u> ¹ , S. Gorcenco ² , H. Ehrencrona ³ , A. Puschmann ² ¹ Helsingborg General Hospital, Department of Neurology, Helsingborg, Sweden, ² Lund University, Skane University Hospital, Department of Neurology, Lund, Sweden, ³ Lund University, Skane University Hospital, Department of Clinical Genetics, Lund, Sweden
P 206 (GPT)	A comprehensive study of the association between autonomic and clinical severity in spinocerebellar ataxia type 3 patients <u>D. Tamuli</u> ¹ , K.K. Deepak ² , A.K. Srivastava ³ ¹ Nalbari College, Zoology, Nalbari, India, ² All India Institute of Medical Sciences, Physiology, New Delhi, India, ³ All India Institute of Medical Sciences, Neurology, New Delhi, India
P 207	Prevalence and clinical correlations of Non-Motor Symptoms in patients with Ataxia: Study in a cohort of Mexican patients <u>H. Pacheco¹</u> , H.R. Martinez Hernandez ² ¹ Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ² Instituto Nacional de Neurologia y Neurocirugia, Mexico City, Mexico

Topic: Tremors, Myoclonus

P 208 (GPT)	Prevalence of essential tremor in rural Gujarat, India <u>S. Desai</u> ¹ , A. Chin ² , S. Raithatha ³ , S. Roy ⁴ , U. Shah ³ , D. Desai ⁵ , A. Deb ² ¹ Shree Krishna Hospital and Pramukhswami Medical College Bhaikaka University, Neurology, Anand, India, ² University Massachusets Chen Medical School, Neurology, Worcester, United States, ³ Shree Krishna Hos- pital and Pramukhswami Medical College Bhaikaka University, Community Medicine, Anand, India, ⁴ Shree Krishna Hospital and Pramukhswami Medical College Bhaikaka University, Central Research, Anand, India, ⁵ Shree Krishna Hospital and Pramukhswami Medical College Bhaikaka University, Medicine, Anand, India
P 209	Clinical tremor-study with gender features in patients with essential tremor in Uzbekistan G. Goyibova ¹ , A. Umarov ² , A. Ismatov ² , D. Tolibov ² ¹ Tashkent Pediatric Medical Institute, Department of Neurology, Tashkent, Uzbekistan, ² Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan
Topic: Gait Distu	rbances and Other Movement Disturbances Disorders
P 210	Pain reduction in adult patients with limb spasticity following single incobotulinum- toxinA injection: analysis of pooled data from phase 2/3 studies <u>J. Wissel</u> ¹ , A. Camões-Barbosa ² , G. Comes ³ , M. Althaus ³ , A. Scheschonka ³ , D.M. Simpson ⁴ ¹ Vivantes Hospital Spandau, Department of Neurorehabilitation and Physical Therapy, Berlin, Germany, ² Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal, ³ Merz Pharmaceuticals GmbH, Frank-
	furt am Main, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, United States
P 211	The need to include functional movement disorders in the differential diagnosis of children presenting to emergency departments <u>J. Brasic</u> ¹ ¹ Johns Hopkins University School of Medicine, The Russell H. Morgan Department of Radiology and Radio- logical Science, Baltimore, United States
P 212	Predictors of early neurological deterioration in Wilson's disease <u>T. Litwin</u> ¹ , T. Ziemssen ² , K. Akgun ² , A. Członkowska ¹ , A. Antos ¹ , J. Bembenek ³ , A. Przybyłkowski ⁴ , M. Skowrońska ¹ , Ł. Smoliński ¹ , I. Kurkowska-Jastrzębska ¹ ¹ Institute Psychiatry and Neurology, 2nd Department of Neurology, Warsaw, Poland, ² University Clinic Carl Gustav Carus & Dresden University of Technology, Center of Clinical Neuroscience, Department of Neu- rology, Dresden, Germany, ³ Institute Psychiatry and Neurology, Department of Neurophysiology, Warsaw, Poland, ⁴ Medical University of Warsaw, Department of Gastroenterology and Internal Medicine, Warsaw, Poland
P 213	Refractory progressive catatonia in autism spectrum disorder <u>J. Brasic</u> ¹ ¹ Johns Hopkins University School of Medicine, The Russell H. Morgan Department of Radiology and Radio- logical Science, Baltimore, United States
P 214	Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: pooled analysis of phase 2/3 studies J. Wissel ¹ , A. Camões-Barbosa ² , G. Comes ³ , M. Althaus ³ , A. Scheschonka ³ , D.M. Simpson ⁴ ¹ Vivantes Hospital Spandau, Berlin, Germany, ² Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal, ³ Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany, ⁴ Icahn School of Medicine at Mount Sinai, New York, United States

P 215	Treatment of cervical dystonia using shorter incobotulinumtoxinA injection intervals improves patient-reported outcomes in those with inadequate benefits from standard intervals <u>C. Comella</u> ¹ , S. Isaacson ² , D. Charles ³ , D. Truong ⁴ , O. Oguh ⁵ , J. Hui6, E. Molho ⁷ , <u>M. Brodsky⁸, E. Furr-Stimming⁹, G. Comes¹⁰, M. Hast¹¹, R. Hauser¹²</u> ¹ Rush University Medical Center, Chicago, United States, ² Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, United States, ³ Vanderbilt University Medical Center, Nashville, United States, ⁴ UC Riverside, Riverside, United States, ⁵ Cleveland Clinic Lou Ruvo Center for Brain Health, Las Ve- gas, United States, ⁶ University of Southern California, Los Angeles, United States, ⁷ Albany Medical Center Neurosciences Institute, Albany, United States, ⁸ Oregon Health & Science University, Portland, United States, ⁹ The University of Texas Health Science Center at Houston, Houston, United States, ¹⁰ Merz Pharma- ceuticals GmbH, Frankfurt am Main, Germany, ¹¹ Merz Pharmaceuticals, LLC, Raleigh, United States, ¹² University of South Florida Health Byrd Institute, Tampa, United States
P 216 (GPT)	Detection of Parkinson's disease using a deep neural network based on gait analysis <u>A. Bajpai¹</u> , G. Bajpai ² ¹ Rajkiya Engineering College, Kannuaj, India, ² CSJM University, Kanpur, India
P 217	Phenotypical and treatment response heterogeneity in a cohort of normal pressure hydrocephalus patients <u>A. Di Maio</u> ¹ ¹ Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
P 218	Optimizing CNS-Delivery by Lactyl Stearate-Coupled Liposomes <u>M. Bhargava</u> ¹ , S. Bhargava ² ¹ GTB Hospital, R&D, Kanpur, India, ² Himalayan University, Pharmacy, Kanpur, India
Topic: Rehabilita	ation, Nursing/Physiotherapy, Other Allied Health; Patient Participation
P 219 (GPT)	Physical interventions for people with Parkinson's disease: results from a Cochrane systematic review and network meta-analysis <u>M. Ernst</u> ¹ , AK. Folkerts ² , M. Roheger ³ , D. Chakraverty ² , F. Krohm ² , J. Caro-Valenzuela ¹ , R. Gollan ² , E. Lieker ² , A. Adams ⁴ , C. Eggers ⁵ , I. Monsef ¹ , A. Dresen ⁶ , N. Skoetz ¹ , E. Kalbe ² ¹ Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germa- ny, ² Medical Psychology Neuropsychology and Gender Studies & Centre for Neuropsychological Diagnos- tics and Intervention (CeNDI), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany, ³ Department of Neurology, University Medicine Greifswald, Greifswald, Germany, ⁴ Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Marburg, Marburg, Germany, ⁶ Insti- tute of Medical Sociology, Health Services Research and Rehabilitation Science, Faculty of Human Scienc- es and Faculty of Medicine and University Hospital, University of Cologne, Cologn
P 220	Using Non-Exercise-Physical-Activity to preserve post-Physical Therapy gains in Parkinson's disease: a feasibility study <u>M. van Emde Boas</u> ¹ , U. Marusic ¹ , M. Muller ¹ , N. Bohnen ¹ ¹ University of Michigan, Functional Neuroimaging, Cognitive & Mobility Lab, Ann Arbor, United States
P 221	Development of a voice and motor speech assessment protocol across an academic health center C. Rountrey ¹ , M. Molett ¹ , <u>B. Kralik¹</u> , A. Spotts ¹ , M. Mateja ¹ , N. Mccarthy ¹ ¹ University of Cincinnati, Communication Sciences and Disorders, Cincinnati, United States

P 222	Vestibular dysfunction: which is the effects of virtual reality? B. Simone Zeigelboim ¹ , M.I. Rodrigues Severiano ² , G.J. Bueno dos Santos ² , <u>H.A. Ghizoni Teive³</u> , J. Stechman-Neto ¹ , R. Sampaio Santos ¹ , C. Miranda de Araújo ¹ , B. Cavalcante-Leão ¹ ¹ Universidade Tuiuti do Paraná, Curitiba, Brazil, ² Instituto Federal do Paraná, Curitiba, Brazil, ³ Universidade Federal do Paraná, Curitiba, Brazil
P 223 (GPT)	Impact of COVID-19 pandemic on eating behavior and body mass index in patients with Parkinson's disease of Northeastern México <u>C.K. Lopez-Botello</u> ¹ , S.A. Castillo-Torres ¹ , I. Estrada-Bellmann ¹ , B.E. Chávez-Luévanos ¹ ¹ Autonomous University of Nuevo León/ University Hospital "Dr. José Eleuterio González", Neurology, Monterrey, Mexico
P 224	Disease severity and gait velocity are predictive of fear of falling avoidance behav- ior in people with parkinsonisms <u>M.R. Landers</u> ¹ , J.V. Rider ² , K. Eckhard ¹ , R. Hammar ¹ , F. Vukojevic ¹ , J. Campbell ³ , J.K. Longhurst ⁴ ¹ University of Nevada, Las Vegas, Physical Therapy, Las Vegas, United States, ² Touro University Nevada, Occupational Therapy, Henderson, United States, ³ Baylor Scott and White Institute for Rehabilitation, Dal- Ias, United States, ⁴ Saint Louis University, Physical Therapy, St. Louis, United States
P 225 (GPT)	Addressing fear of falling avoidance behavior in Parkinson's disease: a theoretical framework to inform clinical practice <u>M.R. Landers</u> ¹ , M.H. Nilsson ^{2,3,4} ¹ University of Nevada, Las Vegas, Physical Therapy, Las Vegas, United States, ² Lund University, Health Sciences, Lund, Sweden, ³ Skåne University Hospital, Memory Clinic (VE minnessjukdomar), Malmö, Sweden, ⁴ Lund University, Skånes Universitetssjukhus, Clinical Memory Research Unit, Clinical Sciences Malmö, Malmö, Sweden

INFORMATION FOR ABSTRACT AUTHORS

The poster and oral poster exhibition (Guided Poster Tours) of the IAPRD Congress 2022 is located in the foyer on the 2nd floor close to the industry exhibition. Posters will be sorted by topics and numbers. The poster exhibition is open to all participants according to the opening times indicated in the daily program overview.

The poster size is 120 cm high and 90 cm wide, DIN A0 (portrait format).

Set-up times for posters /	oral posters
Sunday, 1 May 2022	11:00 - 15:00

Dismantling

T	17.00 10.00
Tuesday, 3 May 2022	17:00 - 18:00

Posters which have not been removed within the indicated time schedule will be removed and disposed.

Oral Poster Presentation (Guided Poster Tours)

Please note that the time allocated for your presentation is a short 2 minute oral presentation followed by Q&A. Given that there are additional abstracts presenting in the same session, we urge you not to exceed the time limit on order to give the other speakers time for their talks.

The Oral Poster Presentation will take place as a poster walk chaired by renowned specialists. Interested delegates can meet the authors during the time of the Oral Poster Presentation (Guided Poster Tours). The presentation will be directly at your poster.

INFORMATION FOR SPEAKERS AND CHAIRPERSONS

Please be at your session room at least 15 minutes prior to the start of your session. Please note that your speaking time as indicated in the email correspondences has to be strictly followed. If you are not certain about the assigned speaking time, please contact your session coordinator, or Severine Weinz at the registration desk.

How to submit your presentation on-site

The speaker's media center is located on the 2nd floor in the meeting room 2.2. We kindly ask all speakers presenting to deliver and view/check their PowerPoint presentations at the speaker's Media Center at least 2 hours prior to the start of their respective session. For sessions starting at 08:00, the presentation should be delivered the previous day.

In order to avoid any delays, speakers are kindly requested to hand in their PowerPoint presentations on a USB stick. If you are bringing your own laptop, your presentation will be transferred on-site in the speaker's Media Center.

The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of presentation. Use of own technical equipment (laptop, MAC) is not allowed.

Sunday, 1 May 2022	09:00 – 17:30
Monday, 2 May 2022	07:00 – 18:00
Tuesday, 3 May 2022	07:00 - 18:00
Wednesday, 4 May 2022	07:30 - 12:00

Opening Hours of the speaker's media center:

The IAPRD acknowledges the generous support of the Parkinson's Foundation, which has provided funding for deserving trainees in the field of movement disorders to attend this congress.



The awards are aimed at promoting participation in the Congress by young researchers worldwide, under the age of 35. The deadline for Travel Grant applications was 9 February 2022.

Further information is available on the congress website.

INDEX OF AUTHORS AND SPEAKERS

Α

Abhishek Bajpai
Adam Boxer20
Agnieszka Antos 14, 32
Aida Kondybayeva27
Alberto Albanese 22, 27, 28
Alexia Duarte 14, 22, 32
Aljeirou Alcachupas
Andreas Puschmann 14, 16, 27
Andres Lozano
Anhar Hassan 28, 33
Anna Castagna
Anna Latorre
Anna Rita Bentivoglio
Arooj Fatima
Avery Kundrick 14, 32

В

Bettina Balint		•	•	•	•		•	•	•	•	•	•	•	•	•	•	.3	3
Bettina Debû			•		•		•		•								.2	4

С

Cecylia Rajczewska-Oleszkiewicz22
Chiara Palmisano
Chitaranjan Mahapatra21
Christine Klein 24, 27
Chunyu Li24

Connie Marras 15, 19, 22	Н
Cynthia Karyna Lopez-Botello	H
	Ha
D	Ha
Daniel Truong 14, 16, 31	Н
Daryl Dakay 14, 32	Н
Dibashree Tamuli	Hi
Dilshoda Akramova 13, 31	Н
Dirk Dressler	Н
Djamilya Aravitskaya 13, 31	Н

Ε

Elan Louis
Elena Moro
Eliša Papić29
Elly Robles23
Elon Wallert21
Emil Ygland Rödström24
Erik Ch. Wolters15
Etienne Hirsch 20, 21
Evžen Růžička28

F

Federica Avantaggiato	13, 31
G	
Gençer Genç	23
Giulia Lazzeri	14, 32

Hector Pacheco Mendoza24 Heinz Reichmann 19, 28 Hitoshi Shimada15 Hubert Fernandez 13, 14, 30, 31, 35 Huifang Shang 14, 35

ï

loannis Isaias3	5
Irena Rektorová 13, 16, 24, 29)
Ivan Rektor 28, 32	2

J

Jaime Kulisevsky
Jakub Malkiewicz 13, 23, 31
Jan Roth 14, 22
Jarosław Sławek 22, 23, 33
Jeffrey Kordower20
Jeryl Ritzi Tan Yu23
Jinyoung Youn 24, 27
Joachim Krauss35
John Caviness
Jonáš Kunst

INDEX OF AUTHORS AND SPEAKERS

Jon Stoessl 21, 35
Joohi Jimenez-Shahed 15, 16, 24, 31, 35
Jörg Wissel33
Junyu Lin
Justyna Kaczyńska

Κ

Kadriye Irem Carus	.33
Kailash Bhatia 27, 32	, 33
Karthik Sreenivasan	.21
Katja Lohmann	.33
Katrina Paumier	.30

L

Leila Montaser Kouhsari	29
Lingyu Zhang	29
Lorraine V. Kalia 14,	19
Lukasz Milanowski	23

Μ

Madara Kalniņa2	2
Malika Giyazova2	3
Mallory Hacker2	9
Maria Fiorella Contarino	0
Marie-Hélène Saint-Hilaire	5
Marina de Koning-Tijssen 20, 3	2
Mario Hero2	3
Mark A. Hirsch 19, 3	0
Mark Hallett 16, 3	0
Mark Lew1	9
Martin Paucar Arce2	7
Marufjon Salokhiddinov2	9
Matej Perovnik 13, 3	1
Meera Matta2	3
Melanie Shackleford	0
Meliza Angelica De Leon 14, 3	2
Merrill R. Landers	0
Merve Sapmaz Atalar	0
Michael Ugrumov2	1
Michael Zech 16, 22, 2	7
Mihaela Simu	0
Moritz Ernst	0
Munisakhon Gulova2	9

Ν

Natalia Madetko	
Natalia Szejko21	
Nils Schnalke	

Ρ

Paola Sandroni 20.20
Pardeep Kumar 13, 31
Pavel Mohr
Per Borghammer
Per Odin
Peter Hedera 14, 33
Peter van Harten
Petr Dušek 27, 32
Petr Kaňovský 13, 24
Pramod Pal 21, 28

Q

Qirui Jiang												.21	
-													

R

Raja Mehanna28
Rajesh Pahwa19
Raymond Rosales
Riadh Gouider27
Roberto Cilia 15, 24
Ronald Postuma19
Roongroj Bhidayasiri15
Ross Elizabeth Cortes21
Roy Alcalay15
Ruth Walker 20, 27, 33
Ryan R. Walsh

S

Sahana Panambur
Sandro Ibrulj31
Sergiu Groppa28
Shinsuke Fujioka
Shivani Arjun30
Shweta Prasad 13, 32
Sihui Chen29
Simon Lewis24
Soaham Desai22
Sonja Mandjikoska 13, 31
Sorina Gorcenco 14, 32

Stanislaw Szlufik 22, 29
Stefan Lorenzl24
Stefan Meng33
Sterre van der Veen20
Stuart Isaacson19

Т

Гапуа Simuni20
Гiago Mestre15
Fiziana De Santis
Fomasz Chmiela23
Гиğçe Saltoğlu 21, 31, 33

V

Valentino Rački23	3
Vincenzo Bonifati	5
Virendra Mishra2	1
Vita Komen23	3
Vlada Meļņikova22	2
Vladimira Vuletić	В

W

Wassilios Meissner	 	.20
Wei Chen	 	.23
William Ondo	 	.25

Х

Xiang Huang	
Y	

Yaroslau Compta	
Yaroslau Compta	13

Ζ

Zheng Jiang	3	0
Zoltan Mari 27, 31	, 33, 3	5
Zvezdan Pirtošek	14, 2	24

GENERAL CONGRESS INFORMATION

REGISTRATION

Registration Counter

The registration counter is located in the Forum Hall Foyer on the 1st floor of the Prague Congress Center and is open during the following times:

Opening hours	
Sunday, 1 May 2022	09:00 – 19:00
Monday, 2 May 2022	07:30 – 18:00
Tuesday, 3 May 2022	07:30 – 18:00
Wednesday, 4 May 2022	07:30 – 12:30

Registration Fees

Registration Types	On-site Price
Regular Congress Ticket	€ 650,00
Reduced Fee**	€ 400,00
Student Ticket***	€ 300,00 (€ 200**)
Allied Health Professionals	€ 475,00

Participants from lower & lower middle income countries: List according to World Bank criteria on our website. * **Students:** Copy of student ID required | **Residents/Fellows/ Trainees**: Born after 1 January 1990 and/or still in training. Copy of official document indicating age or a letter stating training status by employer required.

The registration fee for delegates includes:

- · Access to the scientific sessions
- · Access to the exhibition
- Certificate of attendance
- Welcome reception on Sunday, 1 May 2022, daily coffee breaks and reception prior Grand Parade of Movement Disorders 3 May 2022

Name badge

All participants are requested to wear their name badges at all times during the congress. For organizational and security reasons, we request that all participants and exhibitors wear their badges at all times during congress activities.

A barcode is printed on each name badge. This may be scanned by exhibitors/supporters to access your name, affiliation, country, email address and professional interests provided by you when registering for the congress. We would like to point out that this is entirely voluntary and not compulsory for the participation in corporate events. Delegates can refuse to be scanned at any time. By permitting an exhibitor or supporter to scan your badge, you agree that these details may be used by the company to contact you with relevant product information.

Badges will be colour-coded as follows:



Other Delegates
 Faculty
 Staff

CME ACCREDITATION

Accreditation by the EACCME[®] confers the right to place the following statement in all communication materials including the event website, the event programme and the certificate of attendance. The following statements must be used without revision:

"The XXVII IAPRD World Congress on Parkinson's Disease and Related Disorders, Prague, Czech Republic, 01/05/2022-04/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME[®]) with 21 European CME credits (ECMEC[®]s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity."

"Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME[®] credits to an equivalent number of AMA PRA Category 1 CreditsTM . Information on the process to convert EACCME[®] credit to AMA credit can be found at <u>www.ama-assn.org/education/earn-credit-participation-international-activities</u>.

"Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME[®] forEC-MEC[®]s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada."

Wednesday, 4 May 2022	3 Credits
Tuesday, 3 May 2022	7 Credits
Monday, 2 May 2022	6 Credits
Sunday, 1 May 2022	5 Credits

Certificate of Attendance

To obtain CME accreditation, please complete the CME evaluation form which will be sent to you via email after the congress. The CME certificate will be available for download after completion of the evaluation.

CONGRESS VENUE

Please use "Entrance 5" when entering the venue.

Prague Congress Centre 5. kvetna 1640/65 140 00 Prague 4 Czech Republic

How to get there:

The Prague Congress Centre is adjacent to the Vyšehrad station on Line C of the Prague underground railway network, providing convenient access by public transport from the city's airport and all major rail and bus stations. From the Congress Centre you overlook the city of Prague.

Arriving by plane:

Prague Vaclav Havel airport is located 30 minutes away from the city center. All major European airlines serve Prague, and there are direct oversea flights from Dubai, New York, Philadelphia, Seoul, Shanghai and Toronto.

An Airport express bus directly connects the airport and the main railway station (enabling direct access to the metro C line.)

By taxi:

Use the provider FIX TAXI and Taxi Praha for getting from/to the airport. They operate nonstop at guaranteed prices, based on number of kilometes travelled.

Sales counters of taxi service providers are located at the Terminals 1 and 2 Arrival Halls. Boarding points are clearly marked in front of both Arrival Halls.

Arriving by train:

Prague is well connected by long distance trains among others from Berlin, Hamburg and Vienna. Further details for train travel can be checked at <u>www.cd.cz/en/</u>. Cut your CO_2 emissions by taking the train, by up to 90%.

Public transportation:

The Prague Congress Centre is adjacent to the Vyšehrad station on Line C of the Prague underground railway network. You receive your complimentary public transportation pass once picking up your name badge.

The transfer tickets are valid at the territory of Prague in "**P**", "**0**" and "**B**" zones (covering extensive areas from the city centre to its peripheries, including the Prague Congress Centre area, and all the sights and monuments – please see the "Transit Scheme" attached) on **buses**, **trams**, **subway trains**, **ferries** and the <u>Petrin hill funicular railway</u> (a popular tourist attraction). They are **not valid** on the "PID (or PIT in English)" **railway** (suburban commuter trains) and the **AE – Airport Express** bus line (however they are valid on all the other 4 airport bus lines)!

Networking Events

Welcome Reception Sunday, 1 May 2022 Time: after the Opening Ceremony

The Welcome Reception on Sunday evening is the place to connect with other experts and colleagues from around the globe. Please join us at this informal get-together to greet old friends, meet new colleagues, and exchange impressions of the Congress. Enjoy traditional light Czech snacks and beverages in the casual atmosphere of the Prague Congress Centre. Ticket: Included in Registration Fee

After Work for Residents and Trainees

Monday, 2 May 2022 Time: 18:00 – 19:30 Meeting Point: Prague Congress Center, in front of "Entrance 5"

After a tough congress day local trainees/residents will take small groups of IAPRD delegates to iconic Prague pubs to sample the famous Czech beer (pay on your own and get to know the city). We would like to know how many guides to organize. Would you like to participate in this event? *Fully booked at date of printing. Please ask at the registration desk onsite if tickets are available on short-notice.*



Abstract E-Book

The abstract book contains all accepted abstracts that have been submitted by authors from around the globe on topics related to Parkinson disease and other movement disorders. All abstracts have been reviewed by a panel of reviewers and are now provided on the congress website.

Climate

Prague has a continental climate, with warm, humid summer days. In May the average temperature is 20 $^\circ\text{C}/68$ $^\circ\text{F}.$

Cloakroom

A cloakroom is available next to the registration counter located in the Forum Hall Foyer on the 1st floor of the Prague Congress Center. You can also store you luggage there.

Coffee breaks

Coffee and tea is provided during the breaks in the exhibition area with friendly support by Amneal Pharmaceuticals.

Currency

The official currency is the Czech Koruna CZK. Exchange of foreign currency is available at the airport, train station, at most hotels, banks and exchange offices.

Disclaimer

The Organizers cannot accept liability for injuries or losses of whatever nature incurred by participants, nor for loss of or damage to their luggage and/or personal belongings.

Language

The official language of the International Association Parkinsonism and Related Disorders is English. However, all participants are encouraged to join discussions regardless of their fluency in English, as the exchange of ideas and critical evaluation of presentation is the main purpose of the entire Congress.

Mobile phones

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions.

Personal Insurance

We recommend that all participants take out personal travel and health insurance for their trip.

Press

Journalists should bring their press ID and register at the congress registration counter.
Program Changes

The Organizers cannot assume liability for any changes in the program due to external unforeseen circumstances.

Recording

Cameras, video cameras or audio recording devices are not permitted in the session rooms. Any recording/documentation of sessions is strictly forbidden.

Safety

As in all major cities and congress venues, people should take care of their personal belongings. It is not advised to wear your congress badge outside the XXVII IAPRD Congress activities. Especially in touristic hotspots (Charles bridge, Old town, Prague castle) please be aware of pickpockets.

Smoking Policy

Smoking is not allowed at the venue; the meeting is a non-smoking event.

Visa

The Czech Republic is part of the European Schengen area. The entry formalities for Czech Republic vary accordingly to the country of origin. A letter of invitation can be issued by the congress and registration office.

Wi-Fi and Social Media

Wi-Fi

Complimentary Wi-Fi access is available throughout the venue.SSID:IAPRD2022Password:IAPRD2022

Social Media

y	Twitter:	Follow us @PRDAssociation
		Follow us @ParkinsonismD
in	LinkedIn:	IAPRD Secretariat



About the International Association of Parkinsonism and Related Disorders

More than fifty years ago, the **International Association of Parkinsonism and Related Disorders** was established by the World Federation of Neurology to promote and monitor research developments, as well as to foster communication among neuroscientists in the field. Today, this association is an international, professional association of clinicians, scientists and other healthcare professionals who are interested in neurodegenerative disorders like Parkinson's disease, secondary parkinson-isms, hyperkinetic and hypokinetic movement disorders, and more generally any disorder affecting muscle tone and motor control. The most common clinical disorders and/or symptoms of interest to us are:

- · Genetic and idiopathic Parkinson's disease and other parkinsonism
- · Genetic and idiopathic disorders with dystonia
- · Huntington's disease and other disorders with chorea
- Cerebellar disorders
- Tremor, myoclonus, tics, ballism
- Huntington's diesease, chorea and Gilles de la Tourette's syndrome
- Psychogenic and psychiatric movement disorders
- Movement disorders-related non-motor disorders, such as disorders of the autonomic nervous system, mood disorders, sleep disorders (including: excess daytime sleepiness, REM sleep behaviour disorders, restless legs syndrome, and periodic limb movements) and psychiatric disorders (including: Impulse control disorders, executive dysfunction, dementia, delusions and hallucinations).

The IAPRD has associate members, full members, and honorary members.

Further information are available at www.iaprd.info



IAPRD 2022 Lifetime Achievement Award

Dr. Mark Hallett

Award Lecture:

Sunday, 1 May 2022 during the Opening Ceremony – What makes a movement voluntary or involuntary?

Dr. Mark Hallett is the Chief of the Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. He obtained his MD at Harvard Medical School, had a medical internship at the Peter Bent Brigham Hospital, and a residency in Neurology at the Massachusetts General Hospital. He had fellowships in biophysics at the NIH and clinical neurophysiology at the Institute of Psychiatry in London. From 1976 to 1984, Dr. Hallett was the Chief of the Clinical Neurophysiology Laboratory at the Peter Bent Brigham Hospital, which became the Brigham and Women's Hospital. He progressed at Harvard Medical School to Associate Professor of Neurology.

In 1984, Dr. Hallett came to NINDS, NIH, with tenure, as Chief of the Human Motor Control Section, and in 1988 became Chief of Medical Neurology Branch, both positions he still holds. He was also the NINDS Clinical Director from 1984 to 2000. He has been President of the American Association of Neuromuscular and Electrodiagnostic Medicine, the International Society of Motor Disturbances, the International Parkinson and Movement Disorder Society, and the International Federation of Clinical Neurophysiology, and is currently President of the Functional Neurological Disorder Society. He was appointed an NIH Distinguished Investigator in 2020. He has delivered many named lectures and won many prizes including the World Federation of Neurology Medal for Contribution to Neuroscience in 2019. His research focus is on human motor physiology and the pathophysiology of movement disorders, with recent focus on dystonia and functional neurological disorders. He has a long-standing interest in the nature of voluntary movement.

IAPRD 2022 Melvin Yahr Award Lecture

Dr. Christine Klein

Award Lecture: How has genetics reshaped the field of movement disorders? Tuesday, 3 May 2022, 08:00 – 09:30 Plenary Session 5: How Has Genetics Changed Movement Disorders / Melvin Yahr Lecture

Biosketch

Dr. Christine Klein is a Professor of Neurology and Neurogenetics. She studied medicine in Hamburg, Heidelberg, Luebeck, London, and Oxford (UK) and did internships in Stockholm (Sweden), Rennes (France), Wollongong (Australia) and Vitebsk (Belarus). She moved to Boston from 1997-1999 for a fellowship in Molecular Neurogenetics with Dr. X.O. Breakefield and completed her neurology training at Luebeck University in 2004, followed by a series of summer sabbaticals in movement disorders with Dr. A.E. Lang in Toronto, Canada in 2004-2015. She was appointed Lichtenberg Professor at the Department of Neurology of Luebeck University in 2005, where her research has focused on the clinical and molecular genetics of movement disorders and its functional consequences. In 2009, Dr. Klein was appointed Schilling Professor of Clinical and Molecular Neurogenetics at the University of Luebeck and became Director of the newly founded Institute of Neurogenetics in 2013.

Dr. Klein has published >500 scientific papers and has an h-factor of 99 with ~40,000 citations. She is Deputy Editor of 'Movement Disorders' and 'Science Advances' and former Associate Editor of 'Annals of Neurology' (until 2021), served as chair of the Congress Scientific Program Committee of the 2016/2017 Annual Congresses of the International Parkinson and Movement Disorder Society, is the acting Past-President of the German Neurological Society (~10,000 members) and Chair-elect of the European Section of the International Parkinson and Movement Disorder Society (MDS-ES). She has been elected member of the National Academy of Sciences Leopoldina in 2021. Ten of her former doctoral students or mentees have been promoted to the level of assistant, associate or full professor.

Scientific Program Executive Committee (SPEC)

Andreas Puschmann, Chair (Sweden) Joohi Jimenez-Shahed, Co-Chair (USA) Daniel Truong (USA) Erik Wolters (The Netherlands) Tanya Simuni (USA) Ron Postuma (Canada) Elena Moro (France)

Shinsuke Fujioka (Japan) Huifang Shang (China) Mark Lew (USA) Alberto Albanese (Italy) Petr Kaňovský (Czech Republic) Rajesh Pahwa (USA)

Regional Organizing Committee

Elena Moro, Chair (France) Irena Rektorová, Chair (Czech Republic)

Jan Roth, Chair (Czech Republic) Maja Trošt, Chair (Slovenia)

Awards Committee

Ron Pfeiffer, Chair (USA) Mohit Bhatt (India) Jonathan Carr (South Africa) Susan Fox (Canada)

Abstract Review Committee

Shinsuke Fujioka, Chair (Japan) Joana Siuda, Co-Chair (Poland) Bettina Debu (France) Wassilios Meissner (France) Javier Pagonabarraga (Spain) Hitoshi Shimada (Japan) Nicola Pavese (UK) Diego Torres- Russotto (USA) Fiorella Contarino (The Netherlands) Joohi Jiminez-Shahed (USA) Ron Postuma (Canada) Vincenzo Bonifati (The Netherland) Katerina Markopoulou (USA) Anhar Hassan (USA) Robert Rodnitzky (USA) Carolyn Sue (Australia) Ai Huey Tan (Malaysia) Marie Vidailhet (France)

Maja Trošt (Slovenia) Jinyoung Youn (Republic of Korea) Raja Mehanna (USA) Alberto Albanese (Italy) Riaan van Coller (South Africa) Daniel Zielonka (Poland) Piotr Janik (Poland) Pawel Tacik (Germany) Andreas Puschmann (Sweden) Oksana Suchowersky (Canada) Sorina Gorcenco (Sweden) Yoshikazu Ugawa (Japan) Darius Koziorowski (Poland) Priya Jagota (Thailand) Mark Hirsch (USA)

Industry Liaison Committee Members

Karen Frei, Co-chair (USA) Marie Saint-Hilaire, Co-chair (USA) Alberto Albanese (Italy) Mark Lew (USA) Raja Mehanna (USA)

Fernando Pagan (USA) Jan Roth (Prague) Diego Torres Russotto (USA) Maja Trošt (Slovenia)

World Congress Ambassador Committee

Helio Teive; Laura Silveira (Brazil) Philippe Salles Gándara (Chile) Huifang Shang (China) Oscar Bernal Pacheco; Xiomara Garcia (Colombia) Vladimira Vuletić (Croatia) Frandy Susatia (Indonesia) Shinsuke Fujioka; Genko Oyama (Japan) Beomseok Jeon (Korea, South) Thien Thien Lim; Ai Huey Tan (Malaysia) Daniel Martinez-Ramirez (Mexico) Lara Oyatoye (Nigeria) Gabriela Novotni (North Macedonia) Mathias Toft (Norway)

Gerard Saranza (Philippines) Cristian Falup-Pecurariu (Romania) Igor Petrovic (Serbia) Peter Valkovič (Slovakia) Maja Trošt (Slovenia) Yaroslau Compta (Spain) Per Svenningsson (Sweden) Pattamon Panyakaew (Thailand) Gencer Genc (Turkey) Yevgen Trufanov (Ukraine) Shivam Om Mittal (United Arab Emirates) Valentina Leta (United Kingdom) Tai Tran (Vietnam)

INDUSTRY

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. This section contains information that is promotional in nature, distinct from the scientific/ educational elements of the main CME/CPD event.

Code of Transparency

Interplan publishes the conditions and the scope of the support provided by EFPIA member companies to the IAPRD Congress on a voluntary basis. The publication will be carried out before and during the execution of the Congress.

For the industry partners mentioned above, we are herewith informing about their overall support within the framework of the IAPRD Congress 2022.



Exhibition opening times

Sunday, 1 May 2022	14:30 - 20:30
Monday, 2 May 2022	09:00 - 17:00
Tuesday, 3 May 2022	09:00 - 18:00

SPONSORS / SUPPORTERS

We kindly thank all our sponsors for their support! Sponsor names are in alphabetical order.



This event is supported, in part, by funding from industry. All support will be managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.

CORPORATE SESSIONS / MO-TUE, 2 - 3 MAY 2022

Monday, May 2, 2022

	Corporate Session	South Hall 2B
12:15 - 13:45	Corporate Session Merz Pharmaceuticals GmbH: Understanding Sialorrhea in PD: Impact on patients and families Chair: Stuart Isaacson (Boca Raton, United States)	
12:15 - 12:30	Sialorrhea: impact in PD patients and their families Speaker: Veronica Clark (Buntingford, United Kingdom)	
12:30 - 12:50	Sialorrhea: an underacknowledged symptom in PD Speaker: Stuart Isaacson (Boca Raton, United States)	
12:50 - 13:20	Sialorrhea: practical approach of BoNT treatment Speaker: Bruno Bergmans (Brugge, Belgium)	
13:20 - 13:35	Sialorrhea: holistic approach on patients management Speaker: Veronica Clark (Buntingford, United Kingdom)	
13:35 – 13:45	Sialorrhea: Q&A session Speaker: Stuart Isaacson (Boca Raton, United States)	
	Corporate Session	South Hall 2A
12:15 - 12:30	Corporate Session Medtronic: BrainSense™ Technology in Clinica Introduction: Robert Jech (Prague, Czech Republic)	I Practice
12:30 - 13:00	BrainSense overview and Features Speaker: <i>Maria Fiorella Contarino (Leiden, The Netherlands)</i>	
13:00 - 13:30	BrainSense in Practice and Closed loop DBS Speaker: Joohi Jimenez-Shahed (New York, United States)	
13:30 - 13:45	Panel Discussions Speaker: Robert Jech (Prague, Czech Republic)	
	Tuesday, May 3, 2022	
	Corporate Session	South Hall 2B
12:15 – 13:45	Corporate Session Britannia Pharmaceuticals Ltd: Reframing the treatment paradigm – the rationale for earlier use of device-aided therapy in advanced Parkinson's disease Chair: Teus van Laar (Groningen, Netherlands)	
12:15 - 12:30	Welcome & introductions Focus on the patient journey – how can we extend the quality-of-life Speaker: Teus van Laar (The Netherlands)	window in PD?
12:30 - 12:50	Timing the transition to device-aided therapies – pros, cons and p clinical practice Speaker: Norbert Kovács (Pécs, Hungary)	bitfalls in

CORPORATE SESSIONS / MO-TUE, 2 - 3 MAY 2022

12:50 - 13:10	The future of intrajejunal therapy – the rationale for levodopa sp Speaker: <i>Maja Trošt (Ljubljana, Slovenia)</i>	paring		
13:10 - 13:30	The non-surgical approach to device-aided Parkinson's disease management Speaker: József Szász (Târgu-Mureş, Romania)			
13:30 - 13:45	Question & answer session with the faculty Speaker: Teus van Laar (Groningen, The Netherlands)			
	Corporate Session	South Hall 2A		
12:15 - 13:45	Corporate Session Abbott: Access to care. Telehealth in Deep Brain Stimulation.			
Is tele-medicine beneficial and useful for movement disorder patients? Speaker: Alfonso Fasano (Toronto, Canada)				
	Remote management of DBS systems enabling technologies Speaker: Daniel Weiss (Tübingen, Germany)			
	Modifying the long-term disease courses through individualized toring and programming Speaker: Cristina Torres Diaz (Madrid, Spain)	l remote moni-		
	Panel discussion			
	Closing Remarks			

IMPRINT AND DATA PROTECTION

Organizer of the scientific conference

IAPRD IAPRD Secretariat 15403 N.McKinnon Road Mead, WA USA E-Mail: machapm@comcast.net Website: www.iaprd.info



Congress and Exhibition Office

INTERPLAN Congress, Meeting & Event Management AG Office Hamburg Sachsenstrasse 6, 20097 Hamburg, Germany Phone: +49 40 325092-57 / Fax: +49 40 325092-44 E-mail: IAPRD@interplan.de Website: www.interplan.de



Data Protection

INTERPLAN AG handles all personal data according to the laws of § 4 under the Federal Data Protection Act. For your registration to a congress organized by Interplan, the collecting, saving and processing of your personal data is imperative. This is done solely as a means of the organization and completion of the event. The collected data will only be passed onto a third party, who is directly involved with the running of the congress and when the organizational procedure makes this necessary (operator, hotel, visa, social program etc.).

The legislator requires us to obtain the participant's consent. The registration to a congress organized by us is not possible if we do not get this. When registering you declare the following: I hereby declare my consent that all the information made by me to my person within the handling of the above mentioned congress is filed, saved, processed and the demands made above can correspondingly be passed onto a third party. I agree to receive information on future congresses related to the subject of this event.

Declaration of consent can be retracted at any time by sending a message to Interplan AG, Landsberger Strasse 155, 80687 München, iaprd@interplan.de





WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS





www.iaprd-world-congress.com

2023



